beta

AMRN

Amarin Corporation plc

Amrn

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 11-01-2018 08-01-2018 05-02-2018 02-27-2018 11-01-2017 08-02-2017 05-03-2017
Actual EPS -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.08 -0.12 -0.08 -0.08 -0.04 -0.05 -0.08
Consensus EPS -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.11 -0.1 -0.08 -0.05 -0.05 -0.06 -0.07
Estimated EPS -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.11 -0.1 -0.08 -0.05 -0.05 -0.06 -0.07
Number of Estimates 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 4 3 3
EPS Surprise -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 -$0.03 $0.03 -$0.02 -$0.03 $0.01 $0.01 -$0.01

Stats

Summary

Amarin Corp PLC is a biopharmaceutical company with expertise in lipid science. The Company is engaged in commercialization and development of therapeutics to improve cardiovascular health.

Market Cap: 1.16 Billion

Primary Exchange: NASDAQ Global Market

Website: http://www.amarincorp.com

Shares Outstanding: 271 Million

Float: 269 Million

Dividend: 0.0 (0.0%)

Beta: 0.601547

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 7.41 Million

Ethical Flags

Animal testing

Longest drawdown: 1422 trading days

From: 2013-01-17 To: 2018-09-21

Lowest Point:

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-04-23 07:03:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN ) for violations of 10(b) and 20(a) of the Secur… read more...

Concert And Processa: Pentoxifylline Reborn

via: SeekingAlpha at 2019-04-17 09:06:58:000

In this article, Ill present a way to invest on a drug that seems to have lots of potential, but has already lost patent protection. Ill also present a way to more generically invest in a strategy that allows taking advantage of other similar situations. The Drug - Pentoxi… read more...

Concert And Processa: Pentoxifylline Reborn

via: SeekingAlpha at 2019-04-17 09:06:58:000

In this article, Ill present a way to invest on a drug that seems to have lots of potential, but has already lost patent protection. Ill also present a way to more generically invest in a strategy that allows taking advantage of other similar situations. The Drug - Pentoxi… read more...

Concert And Processa: Pentoxifylline Reborn

via: SeekingAlpha at 2019-04-17 09:06:58:000

In this article, Ill present a way to invest on a drug that seems to have lots of potential, but has already lost patent protection. Ill also present a way to more generically invest in a strategy that allows taking advantage of other similar situations. The Drug - Pentoxi… read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline - AMRN

via: PR Newswire at 2019-04-09 16:51:00:000

NEW YORK , April 10, 2019 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN) and certain of its officers. The class action, filed in United States District Court, District of … read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline - AMRN

via: PR Newswire at 2019-04-09 16:51:00:000

NEW YORK , April 10, 2019 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN) and certain of its officers. The class action, filed in United States District Court, District of … read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline - AMRN

via: PR Newswire at 2019-04-09 16:51:00:000

NEW YORK , April 10, 2019 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN) and certain of its officers. The class action, filed in United States District Court, District of … read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

via: Business Wire at 2019-04-04 10:59:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company")(NASDAQ:AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. … read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

via: Business Wire at 2019-04-04 10:59:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company")(NASDAQ:AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. … read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

via: Business Wire at 2019-04-04 10:59:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company")(NASDAQ:AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. … read more...

Amarin: Update To Standards Of Medical Care In Diabetes Gives Vascepa A Boost

via: SeekingAlpha at 2019-04-03 11:38:54:000

Amarin ( AMRN ) continues to make progress in terms of both Vascepa sales and in seeing REDUCE-IT's results being well received by the medical community. The American Diabetes Association updated the Standards of Medical Care in Diabetes with a recommendation to consider using icosapent ethy… read more...

Building A Bulletproof Portfolio Around Wells Fargo

via: SeekingAlpha at 2019-04-02 06:42:35:000

Wells Fargo celebrates the Year of the Pig (image via Wells Fargo's Twitter page ) WFC And The Hedged Portfolio Method Last August, I wrote about the performance of a bulletproof, or hedged, portfolio built around a position in AT&T (T) in 2017 and presented a new one, which fini… read more...

Amarin: Biotech's 'Good News Bears' Is Bad News For Bears

via: SeekingAlpha at 2019-04-02 05:59:52:000

Note: The following article was first made available to members of The Formula on March 26. Read: ACC Slides Conviction Slides Introduction A successful investment in Amarin ( AMRN ) hinges on the following: Vascepa will receive a favorable label expansion Quar… read more...

Amarin's Vascepa granted priority review status from Health Canada

via: SeekingAlpha at 2019-04-01 04:21:38:000

Health Canada grants priority review status for Amarin's (NASDAQ: AMRN ) licensee, HLS Therapeutics' ( OTCPK:HLTRF ) New Drug Submission (NDS) for Vascepa (icosapent ethyl) capsules. More news on: Amarin Corporation plc, HLS Therapeutics Inc., Healthcare stocks news, … read more...

CHMP affirms opinion that omega-3 fatty acid ineffective after heart attack

via: SeekingAlpha at 2019-03-29 05:00:37:000

In a re-examination of its original recommendation released in December 2018, the European Medicines Agency's advisory group CHMP confirms its view that omega-3 fatty acid medicines containing a combination of an ethyl ester of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA… read more...

CHMP affirms opinion that omega-3 fatty acid ineffective after heart attack

via: SeekingAlpha at 2019-03-29 05:00:37:000

In a re-examination of its original recommendation released in December 2018, the European Medicines Agency's advisory group CHMP confirms its view that omega-3 fatty acid medicines containing a combination of an ethyl ester of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA… read more...

CHMP affirms opinion that omega-3 fatty acid ineffective after heart attack

via: SeekingAlpha at 2019-03-29 05:00:37:000

In a re-examination of its original recommendation released in December 2018, the European Medicines Agency's advisory group CHMP confirms its view that omega-3 fatty acid medicines containing a combination of an ethyl ester of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA… read more...

Amarin files U.S. application for expanded label for Vascepa

via: SeekingAlpha at 2019-03-28 13:03:30:000

Amarin (NASDAQ: AMRN ) has filed a supplemental marketing application with the FDA seeking a cardiovascular (CV) benefit claim for Vascepa (icosapent ethyl) based on the results from the large-scale REDUCE-IT trial. More news on: Amarin Corporation plc, Healthcare stocks news, Stocks o… read more...

LULU, AMRN and FIVE among premarket gainers

via: SeekingAlpha at 2019-03-28 05:16:20:000

Euro Tech Holdings (NASDAQ: CLWT ) +145% . More news on: Euro Tech Holdings Company Limited, Tenax Therapeutics, Inc., Quantenna Communications, Inc., Stocks on the move, Read more … read more...

Stocks making the biggest moves after hours: Lululemon, PVH and more

via: CNBC at 2019-03-27 13:56:41:000

No summary available. read more...

Amarin up 3% on addition of Vascepa to SOC guidelines for diabetes-related CV risk

via: SeekingAlpha at 2019-03-27 11:52:59:000

Amarin ( AMRN +3% ) is up on modestly higher volume following an announcement from the American Diabetes Association adding Vascepa (icosapent ethyl) to its standard-of-care recommendation to reduce cardiovascular (CV) risk in diabetics with atherosclerotic CV disease or other risk facto… read more...

Biotech M&A Theme Builds Momentum

via: SeekingAlpha at 2019-03-26 03:35:37:000

(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We … read more...

Lifshitz & Miller LLP Announces Investigation of Amarin Corporation plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., and The Kraft Heinz Company

via: PR Newswire at 2019-03-22 10:14:00:000

NEW YORK , March 22, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amarin administered an active agent to their placebo group during the Vascepa tr… read more...

Lifshitz & Miller LLP Announces Investigation of Amarin Corporation plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., and The Kraft Heinz Company

via: PR Newswire at 2019-03-22 10:14:00:000

NEW YORK , March 22, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amarin administered an active agent to their placebo group during the Vascepa tr… read more...

Lifshitz & Miller LLP Announces Investigation of Amarin Corporation plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., and The Kraft Heinz Company

via: PR Newswire at 2019-03-22 10:14:00:000

NEW YORK , March 22, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amarin administered an active agent to their placebo group during the Vascepa tr… read more...

Lifshitz & Miller LLP Announces Investigation of Amarin Corporation plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., and The Kraft Heinz Company

via: PR Newswire at 2019-03-22 10:14:00:000

NEW YORK , March 22, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amarin administered an active agent to their placebo group during the Vascepa tr… read more...

More Biogen downgrades in premarket analyst action

via: SeekingAlpha at 2019-03-22 04:43:18:000

Amarin (NASDAQ: AMRN ) initiated with Buy rating and $27 (44% upside) price target at Stifel citing its allure as an acquisition target. Shares down 1% premarket. More news on: Amarin Corporation plc, Varian Medical Systems, Inc., Biogen Inc., Healthcare stocks news, Stocks on … read more...

More Biogen downgrades in premarket analyst action

via: SeekingAlpha at 2019-03-22 04:43:18:000

Amarin (NASDAQ: AMRN ) initiated with Buy rating and $27 (44% upside) price target at Stifel citing its allure as an acquisition target. Shares down 1% premarket. More news on: Amarin Corporation plc, Varian Medical Systems, Inc., Biogen Inc., Healthcare stocks news, Stocks on … read more...

More Biogen downgrades in premarket analyst action

via: SeekingAlpha at 2019-03-22 04:43:18:000

Amarin (NASDAQ: AMRN ) initiated with Buy rating and $27 (44% upside) price target at Stifel citing its allure as an acquisition target. Shares down 1% premarket. More news on: Amarin Corporation plc, Varian Medical Systems, Inc., Biogen Inc., Healthcare stocks news, Stocks on … read more...

More Biogen downgrades in premarket analyst action

via: SeekingAlpha at 2019-03-22 04:43:18:000

Amarin (NASDAQ: AMRN ) initiated with Buy rating and $27 (44% upside) price target at Stifel citing its allure as an acquisition target. Shares down 1% premarket. More news on: Amarin Corporation plc, Varian Medical Systems, Inc., Biogen Inc., Healthcare stocks news, Stocks on … read more...

AMARIN ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights

via: Business Wire at 2019-03-22 02:00:00:000

Gibbs Law Group filed the only class action lawsuit to date against Amarin Corporation (NASDAQ: AMRN). The suit is on behalf of investors who purchased or acquired Amarin securities from September 24, 2018, through November 8, 2018. The lawsuit seeks to recover damages for Amarin investors u… read more...

AMARIN ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights

via: Business Wire at 2019-03-22 02:00:00:000

Gibbs Law Group filed the only class action lawsuit to date against Amarin Corporation (NASDAQ: AMRN). The suit is on behalf of investors who purchased or acquired Amarin securities from September 24, 2018, through November 8, 2018. The lawsuit seeks to recover damages for Amarin investors u… read more...

AMARIN ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights

via: Business Wire at 2019-03-22 02:00:00:000

Gibbs Law Group filed the only class action lawsuit to date against Amarin Corporation (NASDAQ: AMRN). The suit is on behalf of investors who purchased or acquired Amarin securities from September 24, 2018, through November 8, 2018. The lawsuit seeks to recover damages for Amarin investors u… read more...

AMARIN ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights

via: Business Wire at 2019-03-22 02:00:00:000

Gibbs Law Group filed the only class action lawsuit to date against Amarin Corporation (NASDAQ: AMRN). The suit is on behalf of investors who purchased or acquired Amarin securities from September 24, 2018, through November 8, 2018. The lawsuit seeks to recover damages for Amarin investors u… read more...

Amarin up 2% on new REDUCE -IT data

via: SeekingAlpha at 2019-03-18 05:24:53:000

Amarin (NASDAQ: AMRN ) is up 2% premarket on modest volume on the heels of new data from the large-scale REDUCE-IT study of Vascepa (icosapent ethyl). The results were presented at the American College of Cardiology Annual Scientific Sessions in New Orleans. More news on: Ama… read more...

Amarin up 2% on new REDUCE -IT data

via: SeekingAlpha at 2019-03-18 05:24:53:000

Amarin (NASDAQ: AMRN ) is up 2% premarket on modest volume on the heels of new data from the large-scale REDUCE-IT study of Vascepa (icosapent ethyl). The results were presented at the American College of Cardiology Annual Scientific Sessions in New Orleans. More news on: Ama… read more...

Amarin up 2% on new REDUCE -IT data

via: SeekingAlpha at 2019-03-18 05:24:53:000

Amarin (NASDAQ: AMRN ) is up 2% premarket on modest volume on the heels of new data from the large-scale REDUCE-IT study of Vascepa (icosapent ethyl). The results were presented at the American College of Cardiology Annual Scientific Sessions in New Orleans. More news on: Ama… read more...

Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT(TM)

via: PR Newswire at 2019-03-18 05:00:00:000

BEDMINSTER, N.J. and DUBLIN , March 18, 2019 /PRNewswire/ -- Amarin Corporation plc (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa (icosapent ethyl), the REDUCE-IT study, showing that Vascepa provided… read more...

Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT(TM)

via: PR Newswire at 2019-03-18 05:00:00:000

BEDMINSTER, N.J. and DUBLIN , March 18, 2019 /PRNewswire/ -- Amarin Corporation plc (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa (icosapent ethyl), the REDUCE-IT study, showing that Vascepa provided… read more...

Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT(TM)

via: PR Newswire at 2019-03-18 05:00:00:000

BEDMINSTER, N.J. and DUBLIN , March 18, 2019 /PRNewswire/ -- Amarin Corporation plc (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa (icosapent ethyl), the REDUCE-IT study, showing that Vascepa provided… read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

via: PR Newswire at 2019-03-15 13:25:00:000

NEW YORK , March 15, 2019 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company")(NASDAQ:AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities cla… read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

via: PR Newswire at 2019-03-15 13:25:00:000

NEW YORK , March 15, 2019 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company")(NASDAQ:AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities cla… read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

via: PR Newswire at 2019-03-15 13:25:00:000

NEW YORK , March 15, 2019 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company")(NASDAQ:AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities cla… read more...

Robbins Arroyo LLP: Amarin Corporation plc (AMRN) Sued for Misleading Shareholders

via: Business Wire at 2019-03-15 10:46:00:000

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Amarin Corporation plc (NASDAQ: AMRN) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between September 24, 2018 and November 9, 2018. Amarin dev… read more...

Robbins Arroyo LLP: Amarin Corporation plc (AMRN) Sued for Misleading Shareholders

via: Business Wire at 2019-03-15 10:46:00:000

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Amarin Corporation plc (NASDAQ: AMRN) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between September 24, 2018 and November 9, 2018. Amarin dev… read more...

Robbins Arroyo LLP: Amarin Corporation plc (AMRN) Sued for Misleading Shareholders

via: Business Wire at 2019-03-15 10:46:00:000

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Amarin Corporation plc (NASDAQ: AMRN) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between September 24, 2018 and November 9, 2018. Amarin dev… read more...

Amarin Corporation PLC (AMRN) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-13 12:17:24:000

The following slide deck was published by Amarin Corporation plc in conjunction with this Read more … read more...

Amarin Corporation PLC (AMRN) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-13 12:17:24:000

The following slide deck was published by Amarin Corporation plc in conjunction with this Read more … read more...

Amarin Corporation PLC (AMRN) Presents at Cowen Health Care Broker Conference Call - (Transcript)

via: SeekingAlpha at 2019-03-13 10:23:09:000

Amarin Corporation PLC (AMRN) Cowen Health Care Conference March 13, 2019, 08:00 ET Company Participants John Thero - President, CEO & Director Conference Call Participants Presentation Unidentified Analyst Good morning, everyone, and welcome to Cowen's 2019 Health… read more...

Amarin Corporation PLC (AMRN) Presents at Cowen Health Care Broker Conference Call - (Transcript)

via: SeekingAlpha at 2019-03-13 10:23:09:000

Amarin Corporation PLC (AMRN) Cowen Health Care Conference March 13, 2019, 08:00 ET Company Participants John Thero - President, CEO & Director Conference Call Participants Presentation Unidentified Analyst Good morning, everyone, and welcome to Cowen's 2019 Health… read more...

Is Amarin's Prescription Growth Going To Stall, Or Is It Just Getting Started?

via: SeekingAlpha at 2019-03-11 17:00:44:000

On February 27, Amarin Corporation ( AMRN ) reported its fourth-quarter and full-year 2018 financial results and operations update. Amarin had previously released preliminary 2018 results on January 4 th , which included revenue guidance for 2019. Many investors felt this initial guidance … read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

via: Business Wire at 2019-03-11 13:45:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company") (NASDAQ:AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-03-08 06:57:15:000

Noteworthy events during the week of March 10 - 16 for healthcare investors. More news on: Regeneron Pharmaceuticals, Inc., Sanofi, Roche Holding Ltd ADR, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-03-08 06:57:15:000

Noteworthy events during the week of March 10 - 16 for healthcare investors. More news on: Regeneron Pharmaceuticals, Inc., Sanofi, Roche Holding Ltd ADR, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-03-08 06:57:15:000

Noteworthy events during the week of March 10 - 16 for healthcare investors. More news on: Regeneron Pharmaceuticals, Inc., Sanofi, Roche Holding Ltd ADR, Healthcare stocks news, , Read more … read more...

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Amarin Corporation plc (AMRN)

via: Business Wire at 2019-03-05 14:40:00:000

Glancy Prongay & Murray LLP (GPM)reminds investors of the April 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Amarin Corporation plc (Amarin or the Company) (NASD… read more...

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Amarin Corporation plc (AMRN)

via: Business Wire at 2019-03-05 14:40:00:000

Glancy Prongay & Murray LLP (GPM)reminds investors of the April 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Amarin Corporation plc (Amarin or the Company) (NASD… read more...

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amarin Corporation plc (AMRN)

via: Business Wire at 2019-03-04 12:02:00:000

Law Offices of Howard G. Smithreminds investors of the April 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN ) securities be… read more...

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amarin Corporation plc (AMRN)

via: Business Wire at 2019-03-04 12:02:00:000

Law Offices of Howard G. Smithreminds investors of the April 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN ) securities be… read more...

Amarin Corporation PLC (AMRN) Presents at Leerink Partners Global Healthcare Brokers Conference Call - (Transcript)

via: SeekingAlpha at 2019-03-02 19:46:06:000

Amarin Corporation PLC (AMRN) Leerink Partners Global Healthcare Conference Call February 28, 2019, 09:30 ET Company Participants John Thero - CEO Conference Call Participants Presentation Unidentified Analyst Good money everyone thanks for joining us. The next session … read more...

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Amarin Corporation plc Investors (AMRN)

via: Business Wire at 2019-03-01 14:40:00:000

Glancy Prongay & Murray LLP (GPM), a global investors rights law firm,announces that a class action lawsuit has been filed on behalf of investors that acquired Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN ) securiti… read more...

AMARIN INVESTOR ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights

via: Business Wire at 2019-03-01 12:00:00:000

Gibbs Law Group filed the only class action lawsuit to date against Amarin Corporation (NASDAQ: AMRN). The suit is on behalf of investors who purchased or acquired Amarin securities from September 24, 2018, through November 8, 2018. The lawsuit seeks to recover damages for Amarin investors u… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Amarin Corporation plc Investors (AMRN)

via: Business Wire at 2019-02-27 17:08:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Amarin Corporation plc (NASDAQ: AMRN ) (Amarin or the Company) securities between September 24, 2018 and November 8, 2018 , inclusive (t… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Amarin Corporation plc Investors (AMRN)

via: Business Wire at 2019-02-27 17:08:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Amarin Corporation plc (NASDAQ: AMRN ) (Amarin or the Company) securities between September 24, 2018 and November 8, 2018 , inclusive (t… read more...

Amarin Corporation PLC (AMRN) CEO John Thero on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-27 14:55:05:000

Amarin Corporation PLC (AMRN) Q4 2018 Earnings Conference Call February 27, 2019 07:30 AM ET Company Participants Elisabeth Schwartz - IR John Thero - CEO Mike Kalb - CFO Aaron Berg - CCO Craig Granowitz - CMO Joe Kennedy - General Counsel Conference Call Participants … read more...

Amarin Corporation PLC (AMRN) CEO John Thero on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-27 14:55:05:000

Amarin Corporation PLC (AMRN) Q4 2018 Earnings Conference Call February 27, 2019 07:30 AM ET Company Participants Elisabeth Schwartz - IR John Thero - CEO Mike Kalb - CFO Aaron Berg - CCO Craig Granowitz - CMO Joe Kennedy - General Counsel Conference Call Participants … read more...

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-02-27 14:25:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN ) for violations of 10(b) and 20(a) of the Securities Exchang… read more...

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-02-27 14:25:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN ) for violations of 10(b) and 20(a) of the Securities Exchang… read more...

Amarin's Q4 2018 Earnings Report Unlikely To Contain Surprises

via: SeekingAlpha at 2019-02-27 12:38:30:000

I don't really expect any major surprises with Amarin's ( AMRN ) Q4 2018 earnings report . Vascepa's new prescription growth has been tracking well, but it is probably too early for Amarin to make a major increase in its full-year 2019 revenue guidance. There may be some discussion about posi… read more...

Amarin's Q4 2018 Earnings Report Unlikely To Contain Surprises

via: SeekingAlpha at 2019-02-27 12:38:30:000

I don't really expect any major surprises with Amarin's ( AMRN ) Q4 2018 earnings report . Vascepa's new prescription growth has been tracking well, but it is probably too early for Amarin to make a major increase in its full-year 2019 revenue guidance. There may be some discussion about posi… read more...

Amarin Corporation PLC 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-27 10:01:30:000

The following slide deck was published by Amarin Corporation PLC in conjunction with their 2018 Q4 earnings Read more … read more...

Amarin Corporation PLC 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-27 10:01:30:000

The following slide deck was published by Amarin Corporation PLC in conjunction with their 2018 Q4 earnings Read more … read more...

Amarin up 4% on Q4 results

via: SeekingAlpha at 2019-02-27 05:56:44:000

Amarin ( AMRN ) Q4 results : Revenues: $77.3M (+43.4%); Product revenue: $77.1M (+44.1%); Licensing revenue: $0.2M (-50.0%). More news on: Amarin Corporation PLC, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Amarin up 4% on Q4 results

via: SeekingAlpha at 2019-02-27 05:56:44:000

Amarin ( AMRN ) Q4 results : Revenues: $77.3M (+43.4%); Product revenue: $77.1M (+44.1%); Licensing revenue: $0.2M (-50.0%). More news on: Amarin Corporation PLC, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Amarin misses by $0.02, beats on revenue

via: SeekingAlpha at 2019-02-27 05:11:29:000

Amarin (NASDAQ: AMRN ): Q4 Non-GAAP EPS of -$0.09 misses by $0.02 ; GAAP EPS of -$0.11 misses by $0.04 . More news on: Amarin Corporation PLC, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Amarin misses by $0.02, beats on revenue

via: SeekingAlpha at 2019-02-27 05:11:29:000

Amarin (NASDAQ: AMRN ): Q4 Non-GAAP EPS of -$0.09 misses by $0.02 ; GAAP EPS of -$0.11 misses by $0.04 . More news on: Amarin Corporation PLC, Earnings news and commentary, Healthcare stocks news, Read more … read more...

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-02-26 22:24:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN ) for violations of 10(b) and 20(a) of the Securities Exchang… read more...

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-02-26 22:24:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN ) for violations of 10(b) and 20(a) of the Securities Exchang… read more...

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Amarin Corporation plc - AMRN

via: Business Wire at 2019-02-26 18:24:00:000

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Amarin Corporation plc (NASDAQ: AMRN) from September 24, 2018 through November 9, 2018, inclusive (the Class Period). The lawsuit see… read more...

Amarin Q4 2018 Earnings Preview

via: SeekingAlpha at 2019-02-26 17:30:09:000

Amarin (NASDAQ: AMRN ) is scheduled to announce Q4 earnings results on Wednesday, February 27th, before market open. More news on: Amarin Corporation PLC, Earnings news and commentary, , Healthcare stocks news, Read more … read more...

Notable earnings before Wednesday's open

via: SeekingAlpha at 2019-02-26 17:30:02:000

AES , AMRN , AMT , ANIP , BBY , CHK , CLH , CPB , DF , DNR , DOC , DY , EYE , FTDR , GCP , GTE , HMLP , HPT , HZNP , IONS , LIVN , LOW , LXP , MDCO , MGPI , MIDD , NEWM , NOVT , OCN , ODP , PEG , PGTI , PNM , RDC , SBGI , SHOO , TAST , TJX , UTHR F… read more...

Robbins Arroyo LLP: Amarin Corporation plc (AMRN) Sued for Misleading Shareholders

via: Business Wire at 2019-02-26 16:08:00:000

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Amarin Corporation plc (NasdaqGM: AMRN) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between September 24, 2018 and November 9, 2018. Amarin d… read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amarin Corporation plc - AMRN

via: PR Newswire at 2019-02-25 20:53:00:000

NEW YORK , Feb. 26, 2019 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors ofAmarin Corporation plc ("Amarin" or the "Company")(NASDAQ:AMRN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com &#… read more...

Amarin's Vascepa: Outlook & Rebuttal

via: SeekingAlpha at 2019-02-25 12:16:05:000

Note: The following article was first available to members of The Formula . My Thesis My thesis for a long-term investment in Amarin ( AMRN ) includes the following points: Vascepa's REDUCE-IT trial data changed the landscape of cardiology. Administration of Vascepa, in additi… read more...

AMARIN CORPORATION INVESTOR ALERT: Gibbs Law Group Files Class Action Lawsuit Alleging Violations of Federal Securities Laws

via: Business Wire at 2019-02-22 18:18:00:000

Gibbs Law Group announces that it has filed a class action lawsuit against Amarin Corporation (NASDAQ: AMRN) and certain of its officers and directors. The class action, filed in the United States District Court for the District of New Jersey (No. 2:19-cv-6601), is on behalf of investors who… read more...

AMARIN CORPORATION INVESTOR ALERT: Gibbs Law Group Files Class Action Lawsuit Alleging Violations of Federal Securities Laws

via: Business Wire at 2019-02-22 18:18:00:000

Gibbs Law Group announces that it has filed a class action lawsuit against Amarin Corporation (NASDAQ: AMRN) and certain of its officers and directors. The class action, filed in the United States District Court for the District of New Jersey (No. 2:19-cv-6601), is on behalf of investors who… read more...

AMARIN CORPORATION INVESTOR ALERT: Gibbs Law Group Files Class Action Lawsuit Alleging Violations of Federal Securities Laws

via: Business Wire at 2019-02-22 18:18:00:000

Gibbs Law Group announces that it has filed a class action lawsuit against Amarin Corporation (NASDAQ: AMRN) and certain of its officers and directors. The class action, filed in the United States District Court for the District of New Jersey (No. 2:19-cv-6601), is on behalf of investors who… read more...

Amarin: Vascepa's Strong Growth Reflects The Positive Reactions From Doctors To REDUCE-IT

via: SeekingAlpha at 2019-02-20 06:14:45:000

Amarin ( AMRN ) is seeing pretty strong growth with Vascepa prescriptions, continuing the momentum it has seen since it first released REDUCE-IT top line data. Some questions have been brought up about the potential for supplements taking away from Vascepa sales and whether its sales will grow… read more...

Amarin: Vascepa's Strong Growth Reflects The Positive Reactions From Doctors To REDUCE-IT

via: SeekingAlpha at 2019-02-20 06:14:45:000

Amarin ( AMRN ) is seeing pretty strong growth with Vascepa prescriptions, continuing the momentum it has seen since it first released REDUCE-IT top line data. Some questions have been brought up about the potential for supplements taking away from Vascepa sales and whether its sales will grow… read more...

Amarin: Vascepa's Strong Growth Reflects The Positive Reactions From Doctors To REDUCE-IT

via: SeekingAlpha at 2019-02-20 06:14:45:000

Amarin ( AMRN ) is seeing pretty strong growth with Vascepa prescriptions, continuing the momentum it has seen since it first released REDUCE-IT top line data. Some questions have been brought up about the potential for supplements taking away from Vascepa sales and whether its sales will grow… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Amarin's Underappreciated Breakthrough - Addressing Criticism And A Deep Dive Into Mineral Oil

via: SeekingAlpha at 2019-02-08 10:26:51:000

Overview Confusion and misinformation remain about Amarin Pharmaceuticals ( AMRN ) unexpected breakthrough clinical trial results released last fall for its cardiovascular drug, Vascepa. My previous Seeking Alpha article reviewed the facts. Here, I respond to criticism of Vascep… read more...

Amarin's Underappreciated Breakthrough - Addressing Criticism And A Deep Dive Into Mineral Oil

via: SeekingAlpha at 2019-02-08 10:26:51:000

Overview Confusion and misinformation remain about Amarin Pharmaceuticals ( AMRN ) unexpected breakthrough clinical trial results released last fall for its cardiovascular drug, Vascepa. My previous Seeking Alpha article reviewed the facts. Here, I respond to criticism of Vascep… read more...

Amarin's Underappreciated Breakthrough - Addressing Criticism And A Deep Dive Into Mineral Oil

via: SeekingAlpha at 2019-02-08 10:26:51:000

Overview Confusion and misinformation remain about Amarin Pharmaceuticals ( AMRN ) unexpected breakthrough clinical trial results released last fall for its cardiovascular drug, Vascepa. My previous Seeking Alpha article reviewed the facts. Here, I respond to criticism of Vascep… read more...

Amarin's Underappreciated Breakthrough - Addressing Criticism And A Deep Dive Into Mineral Oil

via: SeekingAlpha at 2019-02-08 10:26:51:000

Overview Confusion and misinformation remain about Amarin Pharmaceuticals ( AMRN ) unexpected breakthrough clinical trial results released last fall for its cardiovascular drug, Vascepa. My previous Seeking Alpha article reviewed the facts. Here, I respond to criticism of Vascep… read more...

Amarin's Underappreciated Breakthrough - Addressing Criticism And A Deep Dive Into Mineral Oil

via: SeekingAlpha at 2019-02-08 10:26:51:000

Overview Confusion and misinformation remain about Amarin Pharmaceuticals ( AMRN ) unexpected breakthrough clinical trial results released last fall for its cardiovascular drug, Vascepa. My previous Seeking Alpha article reviewed the facts. Here, I respond to criticism of Vascep… read more...

Commenting On The Rebuttal To The Bear Thesis On Amarin

via: SeekingAlpha at 2019-02-01 11:37:16:000

I once did some due diligence on Amarin ( AMRN ), to see if there was a gigantic opportunity on the long or short side of that particular story. That due diligence gives me the confidence to comment on Elephant Analytics article Thursday, titled A Rebuttal To The Bear Thesis O… read more...

Commenting On The Rebuttal To The Bear Thesis On Amarin

via: SeekingAlpha at 2019-02-01 11:37:16:000

I once did some due diligence on Amarin ( AMRN ), to see if there was a gigantic opportunity on the long or short side of that particular story. That due diligence gives me the confidence to comment on Elephant Analytics article Thursday, titled A Rebuttal To The Bear Thesis O… read more...

Commenting On The Rebuttal To The Bear Thesis On Amarin

via: SeekingAlpha at 2019-02-01 11:37:16:000

I once did some due diligence on Amarin ( AMRN ), to see if there was a gigantic opportunity on the long or short side of that particular story. That due diligence gives me the confidence to comment on Elephant Analytics article Thursday, titled A Rebuttal To The Bear Thesis O… read more...

Commenting On The Rebuttal To The Bear Thesis On Amarin

via: SeekingAlpha at 2019-02-01 11:37:16:000

I once did some due diligence on Amarin ( AMRN ), to see if there was a gigantic opportunity on the long or short side of that particular story. That due diligence gives me the confidence to comment on Elephant Analytics article Thursday, titled A Rebuttal To The Bear Thesis O… read more...

Commenting On The Rebuttal To The Bear Thesis On Amarin

via: SeekingAlpha at 2019-02-01 11:37:16:000

I once did some due diligence on Amarin ( AMRN ), to see if there was a gigantic opportunity on the long or short side of that particular story. That due diligence gives me the confidence to comment on Elephant Analytics article Thursday, titled A Rebuttal To The Bear Thesis O… read more...

A Rebuttal To The Bear Thesis On Amarin

via: SeekingAlpha at 2019-01-31 09:28:03:000

The bear thesis on Amarin (AMRN) involves a belief that OTC fish/krill oil supplements are a cheaper viable alternative to Vascepa, and as a result, Amarin will have trouble getting doctors to prescribe Vascepa without a huge amount of effort. The bear thesis also involves additional dilution … read more...

Amarin: A Rebuttal To Omega-3 Fans

via: SeekingAlpha at 2019-01-30 15:55:05:000

Bhavneesh Sharma recently wrote a quite bearish report on Amarin ( AMRN ), where he predicted the stock would go from around $17 currently, to $5 over the next two years. Seeking Alpha is a great platform for investors because various contributors of varying backgrounds can present different… read more...

Financial Exchange Stock Talk: Bhavneesh Sharma On Amarin

via: SeekingAlpha at 2019-01-30 00:50:28:000

See Bhavneesh's recent article on Amarin (AMRN) Read more … read more...

Amarin: Rating Sell With $5 Price Target, 2-Year Timeframe (70% Downside)

via: SeekingAlpha at 2019-01-27 20:04:39:000

Amarin ( AMRN ) has been a darling of biotech investors with one of the highest bullish sentiments that I have seen on a stock. I will not go into the details of the background of this stock since I assume that you are familiar with it. Amarin's sole product Vascepa has a proprietary formulati… read more...

Amarin: Rating Sell With $5 Price Target, 2-Year Timeframe (70% Downside)

via: SeekingAlpha at 2019-01-27 20:04:39:000

Amarin ( AMRN ) has been a darling of biotech investors with one of the highest bullish sentiments that I have seen on a stock. I will not go into the details of the background of this stock since I assume that you are familiar with it. Amarin's sole product Vascepa has a proprietary formulati… read more...

Healing The World One Biotech Investment At A Time With Jerome Verony (Podcast)

via: SeekingAlpha at 2019-01-25 07:00:00:000

by Jonathan Liss Coming from a family of medical doctors, I am no stranger to sometimes pedantic conversations about the potential efficacy of a particular drug or therapeutic treatment. Not particularly adept as an investor, my father never seriously entertained the idea of using any… read more...

Healing The World One Biotech Investment At A Time With Jerome Verony (Podcast)

via: SeekingAlpha at 2019-01-25 07:00:00:000

by Jonathan Liss Coming from a family of medical doctors, I am no stranger to sometimes pedantic conversations about the potential efficacy of a particular drug or therapeutic treatment. Not particularly adept as an investor, my father never seriously entertained the idea of using any… read more...

Healing The World One Biotech Investment At A Time With Jerome Verony (Podcast)

via: SeekingAlpha at 2019-01-25 07:00:00:000

by Jonathan Liss Coming from a family of medical doctors, I am no stranger to sometimes pedantic conversations about the potential efficacy of a particular drug or therapeutic treatment. Not particularly adept as an investor, my father never seriously entertained the idea of using any… read more...

Your first trade for Thursday, January 24

via: CNBC at 2019-01-24 09:15:00:000

No summary available. read more...

Amarin: Evaluating The Merits Of A Potential Pfizer Acquisition

via: SeekingAlpha at 2019-01-16 11:48:15:000

Those who do not remember the past are condemned to repeat it. - Benjamin Graham On Jan. 10, 2019, the shares of Amarin Corporation ( AMRN ) rallied over 22% due to the news that Pfizer ( PFE ) is interested in buying out the company. Nevertheless, the share price has been trending down … read more...

Amarin: Evaluating The Merits Of A Potential Pfizer Acquisition

via: SeekingAlpha at 2019-01-16 11:48:15:000

Those who do not remember the past are condemned to repeat it. - Benjamin Graham On Jan. 10, 2019, the shares of Amarin Corporation ( AMRN ) rallied over 22% due to the news that Pfizer ( PFE ) is interested in buying out the company. Nevertheless, the share price has been trending down … read more...

Amarin: Evaluating The Merits Of A Potential Pfizer Acquisition

via: SeekingAlpha at 2019-01-16 11:48:15:000

Those who do not remember the past are condemned to repeat it. - Benjamin Graham On Jan. 10, 2019, the shares of Amarin Corporation ( AMRN ) rallied over 22% due to the news that Pfizer ( PFE ) is interested in buying out the company. Nevertheless, the share price has been trending down … read more...

Does The Bull Survive? Stock Market Outlook 2019

via: SeekingAlpha at 2019-01-11 17:01:16:000

Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...

Does The Bull Survive? Stock Market Outlook 2019

via: SeekingAlpha at 2019-01-11 17:01:16:000

Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...

Does The Bull Survive? Stock Market Outlook 2019

via: SeekingAlpha at 2019-01-11 17:01:16:000

Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...

Does The Bull Survive? Stock Market Outlook 2019

via: SeekingAlpha at 2019-01-11 17:01:16:000

Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...

Does The Bull Survive? Stock Market Outlook 2019

via: SeekingAlpha at 2019-01-11 17:01:16:000

Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...

Spectrum Of Momentum Stocks Dominating The Early Returns For January

via: SeekingAlpha at 2019-01-11 13:31:12:000

The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 12% gains into early January. These gains appear to be primarily based on the strength of momentum and forensic negative stock selections… read more...

Spectrum Of Momentum Stocks Dominating The Early Returns For January

via: SeekingAlpha at 2019-01-11 13:31:12:000

The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 12% gains into early January. These gains appear to be primarily based on the strength of momentum and forensic negative stock selections… read more...

Spectrum Of Momentum Stocks Dominating The Early Returns For January

via: SeekingAlpha at 2019-01-11 13:31:12:000

The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 12% gains into early January. These gains appear to be primarily based on the strength of momentum and forensic negative stock selections… read more...

Spectrum Of Momentum Stocks Dominating The Early Returns For January

via: SeekingAlpha at 2019-01-11 13:31:12:000

The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 12% gains into early January. These gains appear to be primarily based on the strength of momentum and forensic negative stock selections… read more...

Spectrum Of Momentum Stocks Dominating The Early Returns For January

via: SeekingAlpha at 2019-01-11 13:31:12:000

The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 12% gains into early January. These gains appear to be primarily based on the strength of momentum and forensic negative stock selections… read more...

Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference

via: CNBC at 2019-01-11 10:31:00:000

No summary available. read more...

Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference

via: CNBC at 2019-01-11 10:31:00:000

No summary available. read more...

Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference

via: CNBC at 2019-01-11 10:31:00:000

No summary available. read more...

Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference

via: CNBC at 2019-01-11 10:31:00:000

No summary available. read more...

Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference

via: CNBC at 2019-01-11 10:31:00:000

No summary available. read more...

Microcaps dominate midday movers

via: SeekingAlpha at 2019-01-10 12:46:27:000

Gainers: Inpixon (NASDAQ: INPX ) +42% . PLx Pharma (NASDAQ: PLXP ) +31% . Novan (NASDAQ: NOVN ) +24% . AgeX Therapeutics (NYSEMKT: AGE ) +22% . 500.com (NYSE: WBAI ) +25% . Fang Holdings (NYSE: SFUN ) +22% . Veritone (NASDAQ: VERI ) +19% . CooTek (NYSE: CTK ) +17% . SAExplora… read more...

Amarin Corporation PLC (AMRN) CEO John Thero Presents at the 37th Annual JPMorgan Healthcare Conference (Transcript)

via: SeekingAlpha at 2019-01-09 16:43:06:000

Amarin Corporation PLC. (AMRN) 37th Annual JPMorgan Healthcare Conference January 09, 2019, 12:30 AM ET Company Participants John Thero - President and Chief Executive Officer Conference Call Participants Yuko Oku - Associate on the JPMorgan biotech team Presentation Yu… read more...

Amarin: Vascepa Revenues Could Be Significantly Higher Than $350 Million In 2019

via: SeekingAlpha at 2019-01-08 15:18:21:000

Amarin ( AMRN ) recently provided an update about its expected Q4 2018 results along with some guidance for 2019. While Amarin's initial guidance of $350 million in net revenue was below expectations , it only has a limited amount of post REDUCE-IT sales data to work with. The $350 million … read more...

Amarin And The Art Of Low-Balling Guidance - Why 2019 Forecast Are Too Low

via: SeekingAlpha at 2019-01-08 14:04:04:000

One of the Few Times the Rear-View Mirror is More Important than Guidance While there is intense focus on the low-balled guidance Amarin ( AMRN ) released last Friday (2019 sales target of only $350m versus consensus estimates of $417m), the Q4 2018 revenue number grabbed my attention the mo… read more...

Amarin Pharmaceuticals: 2019 Will Be Interesting

via: SeekingAlpha at 2019-01-08 07:44:07:000

Amarin ( AMRN ) has been a name which I have not covered extensively, but recent events make it certainly worthwhile to check the stock out. Reality is that the research results have been pretty good. As investors initially reacted with great enthusiasm to the good results, shares have seen … read more...

3 Things To Watch For Monday In Biotech Land

via: SeekingAlpha at 2019-01-07 05:52:02:000

Most people do not really want freedom, because freedom involves responsibility, and most people are frightened of responsibility . Sigmund Freud, Civilization and Its Discontents It was another roller-coaster week on Wall Street to start off the New Year. Stocks cratered… read more...

Amarin off 7% after hours on soft 2019 outlook for Vascepa

via: SeekingAlpha at 2019-01-04 16:49:43:000

Amarin (NASDAQ: AMRN ) is down 7% after hours on the heels of its announcement of preliminary 2018 results and 2019 forecast, information that will be presented next week at JPM19. More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move, Read more… read more...

Amarin off 7% after hours on soft 2019 outlook for Vascepa

via: SeekingAlpha at 2019-01-04 16:49:43:000

Amarin (NASDAQ: AMRN ) is down 7% after hours on the heels of its announcement of preliminary 2018 results and 2019 forecast, information that will be presented next week at JPM19. More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move, Read more… read more...

Amarin off 7% after hours on soft 2019 outlook for Vascepa

via: SeekingAlpha at 2019-01-04 16:49:43:000

Amarin (NASDAQ: AMRN ) is down 7% after hours on the heels of its announcement of preliminary 2018 results and 2019 forecast, information that will be presented next week at JPM19. More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move, Read more… read more...

Keeping Focused Amidst The Biotech Bear

via: SeekingAlpha at 2018-12-28 06:30:00:000

2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...

Keeping Focused Amidst The Biotech Bear

via: SeekingAlpha at 2018-12-28 06:30:00:000

2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...

Keeping Focused Amidst The Biotech Bear

via: SeekingAlpha at 2018-12-28 06:30:00:000

2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...

Keeping Focused Amidst The Biotech Bear

via: SeekingAlpha at 2018-12-28 06:30:00:000

2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...

Keeping Focused Amidst The Biotech Bear

via: SeekingAlpha at 2018-12-28 06:30:00:000

2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...

Biotech Bonanza: 2019 Outlook On An Uphill Battle

via: SeekingAlpha at 2018-12-20 14:47:33:000

Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...

Biotech Bonanza: 2019 Outlook On An Uphill Battle

via: SeekingAlpha at 2018-12-20 14:47:33:000

Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...

Biotech Bonanza: 2019 Outlook On An Uphill Battle

via: SeekingAlpha at 2018-12-20 14:47:33:000

Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...

The Facts About Amarin's Historic Cariovascular Healthcare Breakthrough

via: SeekingAlpha at 2018-12-20 12:00:42:000

Editor's note: Seeking Alpha is proud to welcome Charles Lyon as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Editor's not… read more...

The Facts About Amarin's Historic Cariovascular Healthcare Breakthrough

via: SeekingAlpha at 2018-12-20 12:00:42:000

Editor's note: Seeking Alpha is proud to welcome Charles Lyon as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Editor's not… read more...

The Facts About Amarin's Historic Cariovascular Healthcare Breakthrough

via: SeekingAlpha at 2018-12-20 12:00:42:000

Editor's note: Seeking Alpha is proud to welcome Charles Lyon as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Editor's not… read more...

European advisory group rescinds authorization for omega-3 fatty acid meds for use after heart attacks

via: SeekingAlpha at 2018-12-14 12:09:26:000

Citing the lack of evidence that they work for the indication, the European Medicines Agency's advisory group CHMP has withdrawn its authorization for the use of omega-3 fatty acid medications to prevent further heart and blood vessel problems in heart attack patients. The meds have been a… read more...

European advisory group rescinds authorization for omega-3 fatty acid meds for use after heart attacks

via: SeekingAlpha at 2018-12-14 12:09:26:000

Citing the lack of evidence that they work for the indication, the European Medicines Agency's advisory group CHMP has withdrawn its authorization for the use of omega-3 fatty acid medications to prevent further heart and blood vessel problems in heart attack patients. The meds have been a… read more...

European advisory group rescinds authorization for omega-3 fatty acid meds for use after heart attacks

via: SeekingAlpha at 2018-12-14 12:09:26:000

Citing the lack of evidence that they work for the indication, the European Medicines Agency's advisory group CHMP has withdrawn its authorization for the use of omega-3 fatty acid medications to prevent further heart and blood vessel problems in heart attack patients. The meds have been a… read more...

European advisory group rescinds authorization for omega-3 fatty acid meds for use after heart attacks

via: SeekingAlpha at 2018-12-14 12:09:26:000

Citing the lack of evidence that they work for the indication, the European Medicines Agency's advisory group CHMP has withdrawn its authorization for the use of omega-3 fatty acid medications to prevent further heart and blood vessel problems in heart attack patients. The meds have been a… read more...

European advisory group rescinds authorization for omega-3 fatty acid meds for use after heart attacks

via: SeekingAlpha at 2018-12-14 12:09:26:000

Citing the lack of evidence that they work for the indication, the European Medicines Agency's advisory group CHMP has withdrawn its authorization for the use of omega-3 fatty acid medications to prevent further heart and blood vessel problems in heart attack patients. The meds have been a… read more...

Amarin: In Good Position To Capitalize On Exceptional REDUCE-IT Results

via: SeekingAlpha at 2018-12-10 19:10:00:000

Amarin ( AMRN ) appears to be in a good position post REDUCE-IT results. It has bolstered its cash balance at the cost of only a minimal amount of dilution. As well, Vascepa's weekly NRx saw another jump after the presentation of detailed REDUCE-IT results. Going forward, I would expect to s… read more...

Amarin: In Good Position To Capitalize On Exceptional REDUCE-IT Results

via: SeekingAlpha at 2018-12-10 19:10:00:000

Amarin ( AMRN ) appears to be in a good position post REDUCE-IT results. It has bolstered its cash balance at the cost of only a minimal amount of dilution. As well, Vascepa's weekly NRx saw another jump after the presentation of detailed REDUCE-IT results. Going forward, I would expect to s… read more...

Amarin: A Poison Pill For The Miracle Pill

via: SeekingAlpha at 2018-12-07 11:06:06:000

Amarin Corporation PLC ( AMRN ) is a small biotechnology company, based in Ireland. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients w… read more...

Amarin: A Poison Pill For The Miracle Pill

via: SeekingAlpha at 2018-12-07 11:06:06:000

Amarin Corporation PLC ( AMRN ) is a small biotechnology company, based in Ireland. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients w… read more...

Amarin: A Poison Pill For The Miracle Pill

via: SeekingAlpha at 2018-12-07 11:06:06:000

Amarin Corporation PLC ( AMRN ) is a small biotechnology company, based in Ireland. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients w… read more...

Amarin: A Poison Pill For The Miracle Pill

via: SeekingAlpha at 2018-12-07 11:06:06:000

Amarin Corporation PLC ( AMRN ) is a small biotechnology company, based in Ireland. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients w… read more...

Amarin Corporation plc (AMRN) CEO John Thero Presents at Citi's 2018 Global Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-12-05 20:55:04:000

Amarin Corporation plc (AMRN) Citis 2018 Global Healthcare Conference December 5, 2018, 02:10 PM ET Executives John Thero - President and Chief Executive Officer Analysts Joel Beatty - Citigroup Presentation Joel Beatty I'm Joel Beatty, one of Citis bi… read more...

Novavax: A Break In The Action

via: SeekingAlpha at 2018-12-03 03:58:13:000

Buy The Decline Novavax ( NVAX ) is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company recently reported quarter 3 earnings earlier this month missing on revenue by $1.89 … read more...

Novavax: A Break In The Action

via: SeekingAlpha at 2018-12-03 03:58:13:000

Buy The Decline Novavax ( NVAX ) is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company recently reported quarter 3 earnings earlier this month missing on revenue by $1.89 … read more...

Novavax: A Break In The Action

via: SeekingAlpha at 2018-12-03 03:58:13:000

Buy The Decline Novavax ( NVAX ) is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company recently reported quarter 3 earnings earlier this month missing on revenue by $1.89 … read more...

Amarin's U.S. Patent Protection For Vascepa

via: SeekingAlpha at 2018-11-30 10:30:00:000

In this article, we discuss Amarin's (AMRN) U.S. patents on Vascepa . From an investor's perspective, the high level story is promising, with protection apparently out to 2030 for 21 of 22 Orange-Book-listed patents. The Vascepa patents include 2 formulation patents and 2 meth… read more...

Amarin's U.S. Patent Protection For Vascepa

via: SeekingAlpha at 2018-11-30 10:30:00:000

In this article, we discuss Amarin's (AMRN) U.S. patents on Vascepa . From an investor's perspective, the high level story is promising, with protection apparently out to 2030 for 21 of 22 Orange-Book-listed patents. The Vascepa patents include 2 formulation patents and 2 meth… read more...

Amarin's U.S. Patent Protection For Vascepa

via: SeekingAlpha at 2018-11-30 10:30:00:000

In this article, we discuss Amarin's (AMRN) U.S. patents on Vascepa . From an investor's perspective, the high level story is promising, with protection apparently out to 2030 for 21 of 22 Orange-Book-listed patents. The Vascepa patents include 2 formulation patents and 2 meth… read more...

Amarin Corporation plc (AMRN) CEO John Thero Presents at Evercore ISI HealthCONx Conference (Transcript)

via: SeekingAlpha at 2018-11-28 16:47:18:000

Amarin Corporation plc (AMRN) Evercore ISI HealthCONx Conference Call November 27, 2018 10:15 AM ET Executives John Thero - CEO Analysts Josh Schimmer - Evercore ISI Presentation Josh Schimmer I think were going to get started. Welcome everyone. Thanks for jo… read more...

Amarin Corporation plc (AMRN) CEO John Thero Presents at Evercore ISI HealthCONx Conference (Transcript)

via: SeekingAlpha at 2018-11-28 16:47:18:000

Amarin Corporation plc (AMRN) Evercore ISI HealthCONx Conference Call November 27, 2018 10:15 AM ET Executives John Thero - CEO Analysts Josh Schimmer - Evercore ISI Presentation Josh Schimmer I think were going to get started. Welcome everyone. Thanks for jo… read more...

Amarin's Vascepa: Reject The Noise And Accept The Facts

via: SeekingAlpha at 2018-11-28 09:38:04:000

Editor's note: Seeking Alpha is proud to welcome Christopher Crocker as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Targ… read more...

Amarin's Vascepa: Reject The Noise And Accept The Facts

via: SeekingAlpha at 2018-11-28 09:38:04:000

Editor's note: Seeking Alpha is proud to welcome Christopher Crocker as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Targ… read more...

Amarin: Dilution From Equity Offering Is Minimal

via: SeekingAlpha at 2018-11-28 09:32:08:000

Amarin's ( AMRN ) equity offering resulted in a 13% decline in its share price (up to a 17% decline at one point), which seems like a drastic overreaction to what is effectively less than a 4% increase in Amarin's share count. Based on its closing price on November 27, Amarin's market cap … read more...

Amarin: Dilution From Equity Offering Is Minimal

via: SeekingAlpha at 2018-11-28 09:32:08:000

Amarin's ( AMRN ) equity offering resulted in a 13% decline in its share price (up to a 17% decline at one point), which seems like a drastic overreaction to what is effectively less than a 4% increase in Amarin's share count. Based on its closing price on November 27, Amarin's market cap … read more...

FIRE Building Portfolio: Initiated Positions In November

via: SeekingAlpha at 2018-11-27 09:10:43:000

Background I am looking at building a portfolio that is high yield and growth-oriented in order to retire within 7 or 8 years. At the point of retiring, this portfolio will transition into a safer distribution yield-based portfolio which is targeted to yield 4% or 5% to cover my daily expe… read more...

Stocks making the biggest move premarket: UTX, AAPL, HIBB, NVS, TSLA & more

via: CNBC at 2018-11-27 07:36:00:000

No summary available. read more...

Amarin prices public offering of ADS

via: SeekingAlpha at 2018-11-27 02:04:18:000

Amarin (NASDAQ: AMRN ) prices its public offering of American Depositary Shares ("ADSs") for gross proceeds of ~$200M. More news on: Amarin Corporation PLC, Healthcare stocks news, Read more … read more...

JinkoSolar, Halozyme and Amarin among after hour movers

via: SeekingAlpha at 2018-11-26 17:40:14:000

More news on: Spirit Airlines, FTE Networks, Inc., JinkoSolar Holding Co., Ltd., Stocks on the move, , Read more … read more...

ClearBridge Small Cap Strategy Portfolio Manager Commentary Q3 2018

via: SeekingAlpha at 2018-11-22 08:20:00:000

Read more … read more...

ClearBridge Small Cap Strategy Portfolio Manager Commentary Q3 2018

via: SeekingAlpha at 2018-11-22 08:20:00:000

Read more … read more...

ClearBridge Small Cap Strategy Portfolio Manager Commentary Q3 2018

via: SeekingAlpha at 2018-11-22 08:20:00:000

Read more … read more...

Insider Weekends: Father-Daughter Team At American Homes 4 Rent Continue Their Buying Spree

via: SeekingAlpha at 2018-11-20 09:04:26:000

Insider buying increased last week, with insiders purchasing $178.94 million of stock compared to $106.85 million in the week prior. Selling also increased, with insiders selling $1.18 billion of stock last week compared to $1.09 billion in the week prior. Sell/Buy Ratio: The insider Sell/… read more...

Insider Weekends: Father-Daughter Team At American Homes 4 Rent Continue Their Buying Spree

via: SeekingAlpha at 2018-11-20 09:04:26:000

Insider buying increased last week, with insiders purchasing $178.94 million of stock compared to $106.85 million in the week prior. Selling also increased, with insiders selling $1.18 billion of stock last week compared to $1.09 billion in the week prior. Sell/Buy Ratio: The insider Sell/… read more...

Amarin May Have Already Won Vascepa Battle Regardless Of FDA Decision

via: SeekingAlpha at 2018-11-20 02:27:35:000

Amarin ( AMRN ) may have already won the battle with the Food and Drug Administration, regardless of whether the FDA approves Vascepa for the coveted label extension that Amarin is seeking. Vascepa, as many are aware, is a fish-oil based medication designed to lower blood triglycerides. At thi… read more...

Amarin May Have Already Won Vascepa Battle Regardless Of FDA Decision

via: SeekingAlpha at 2018-11-20 02:27:35:000

Amarin ( AMRN ) may have already won the battle with the Food and Drug Administration, regardless of whether the FDA approves Vascepa for the coveted label extension that Amarin is seeking. Vascepa, as many are aware, is a fish-oil based medication designed to lower blood triglycerides. At thi… read more...

Total Pharma Tracker's Daily BioPharma Focus: Questions Surrounding Amarin's Trial Data

via: SeekingAlpha at 2018-11-16 10:59:40:000

Amarin ( AMRN ) released complete data from the REDUCE-IT study on November 9. The extended data confirmed the 25% reduction in ischemic incidents figure we had heard earlier, an announcement that had skyrocketed the stock. However, there were two apparent issues with the new data that was i… read more...

Total Pharma Tracker's Daily BioPharma Focus: Questions Surrounding Amarin's Trial Data

via: SeekingAlpha at 2018-11-16 10:59:40:000

Amarin ( AMRN ) released complete data from the REDUCE-IT study on November 9. The extended data confirmed the 25% reduction in ischemic incidents figure we had heard earlier, an announcement that had skyrocketed the stock. However, there were two apparent issues with the new data that was i… read more...

Total Pharma Tracker's Daily BioPharma Focus: Questions Surrounding Amarin's Trial Data

via: SeekingAlpha at 2018-11-16 10:59:40:000

Amarin ( AMRN ) released complete data from the REDUCE-IT study on November 9. The extended data confirmed the 25% reduction in ischemic incidents figure we had heard earlier, an announcement that had skyrocketed the stock. However, there were two apparent issues with the new data that was i… read more...

Total Pharma Tracker's Daily BioPharma Focus: Questions Surrounding Amarin's Trial Data

via: SeekingAlpha at 2018-11-16 10:59:40:000

Amarin ( AMRN ) released complete data from the REDUCE-IT study on November 9. The extended data confirmed the 25% reduction in ischemic incidents figure we had heard earlier, an announcement that had skyrocketed the stock. However, there were two apparent issues with the new data that was i… read more...

QURE, ARNA and CSCO among premarket gainers

via: SeekingAlpha at 2018-11-15 09:26:47:000

uniQure N.V. (NASDAQ: QURE ) +26% after AMT-061 shows positive action in mid-stage hemophilia B study. More news on: uniQure N.V., Arena Pharmaceuticals, Inc., New Age Beverages Corporation, Stocks on the move, , Read more … read more...

Amarin's Mineral Menace

via: SeekingAlpha at 2018-11-15 01:58:40:000

It is extremely important to note that this "mineral oil" menace has been popping its head up after each significant achievement that Amarin (AMRN) has hit. It came about during the Marine Trial, during the Anchor Trial, during the ADCOM, and now again after the REDUCE-IT results were announce… read more...

Amarin: 85% Of Doctors Polled At AHA Conference Intend To Prescribe Vascepa

via: SeekingAlpha at 2018-11-14 13:05:54:000

Amarin Is Now Trading At A 1.3x PER On Our 2022 Estimates And The Recent Drop Is A Buying Opportunity Due to the confusion and misconceptions over the use of mineral oil placebos in the Reduce-It trial, Amarin's (AMRN) stock dropped by 27% over the past two days, despite better than expected… read more...

Amarin up 2% premarket as bargain hunters move in

via: SeekingAlpha at 2018-11-14 08:39:19:000

Amarin (NASDAQ: AMRN ) is up 2% premarket on robust volume as investors take positions following yesterday's 22% selloff stoked by scrutiny of the REDUCE-IT study. More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move, Read more … read more...

Amyris Q3 miss pressures shares, down 31% after hours

via: SeekingAlpha at 2018-11-13 16:45:02:000

Amyris (NASDAQ: AMRN ) Q3 results ($M): Revenue: 14.9 (-38.4%) due mainly to a $7.1M drop in grant/collaboration revenue and a $1.4M drop in renewable product sales. More news on: Amarin Corporation PLC, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Consumer s… read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amarin Corporation - AMRN

via: PR Newswire at 2018-11-13 14:50:00:000

NEW YORK , Nov. 13, 2018 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529,… read more...

Biotech Analysis Central Pharma News: Merrimack's Struggle, Eli Lilly's Setback, Amarin's Issue

via: SeekingAlpha at 2018-11-13 12:33:34:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Merrimack Continues To Struggle Amid 60% Workforce Cut News: Recently, Merrimack Pharmaceuticals ( MACK ) announced a program update in its Q3 earn… read more...

Amarin Corporation PLC (AMRN) CEO John Thero Presents Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association Conference Call (Transcript)

via: SeekingAlpha at 2018-11-13 08:39:06:000

Amarin Corporation PLC (AMRN) Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association November 10, 2018 08:15 PM ET Executives John Thero - President and Chief Executive Officer Steve Ketchum - Chief Scientific Officer Rebe… read more...

As Amarin stock drops, CEO says investors should 'understand our data better'

via: CNBC at 2018-11-12 18:03:00:000

No summary available. read more...

Amarin: Addressing The Mineral Oil Issue

via: SeekingAlpha at 2018-11-12 16:49:11:000

Amarin ( AMRN ) presented and published detailed and resoundingly positive results from its landmark REDUCE-IT trial on Saturday, November 10. The positive effect was observed in the primary MACE+ composite as well as in multiple secondary endpoints, showing a robust benefit for both &#x20… read more...

Amarin selloff pressures Matinas Bio, down 10%

via: SeekingAlpha at 2018-11-12 10:09:05:000

Matinas BioPharma ( MTNB -9.9% ) is down on almost 30% higher volume in apparent sympathy with Amarin ( AMRN -10.8% ) after the latter released results from a large-scale study of Vascepa (icosapent ethyl), a form of omega-3 fatty acid. More news on: Matinas Biopharma Holdings, Inc., A… read more...

Amarin Goes From Solid To Speculative After Full REDUCE-IT Trial Results Released

via: SeekingAlpha at 2018-11-12 10:07:15:000

After the initial Amarin (AMRN) REDUCE-IT study results were published last month, I wrote an article suggesting that the company could be a buyout target for as much as $45 per share. However, in that article, I noted that I was taking the company's preliminary trial results at face value a… read more...

PCG, EIX, BTI, SAP among premarket losers

via: SeekingAlpha at 2018-11-12 09:19:05:000

Lumentum Holdings (NASDAQ: LITE ) -26% after Q2 guidance . More news on: Lumentum Holdings Inc., GNC Holdings, Inc., PG&E Corporation, Stocks on the move, , Top stock market news, Read more … read more...

Amarin down 14% premarket on scrutiny of REDUCE-IT study

via: SeekingAlpha at 2018-11-12 08:51:08:000

Amarin (NASDAQ: AMRN ) is off 14% premarket on robust volume in apparent reaction to the details of REDUCE-IT, the large-scale study showing the cardiovascular benefits of Vascepa (icosapent ethyl) in statin-treated patients with triglyceride levels between 135 mg/dL and 499 mg/d… read more...

Amarin's Vascepa reduced major adverse cardiovascular events by 25% in large-scale REDUCE-IT study

via: SeekingAlpha at 2018-11-11 16:18:06:000

The data were presented at the AHA Scientific Sessions in Chicago and simultaneously published in the New England Journal of Medicine . More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move, Read more … read more...

Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT(TM) Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint

via: PR Newswire at 2018-11-11 10:32:00:000

CHICAGO , Nov. 11, 2018 /PRNewswire/ -- Amarin Corporation plc(NASDAQ: AMRN), announced today the primary results from the Vascepa (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT, following presentation of the late-breaking clinical trial results at the… read more...

Amarin's REDUCE-IT Trial: Something Fishy?

via: SeekingAlpha at 2018-11-11 09:46:21:000

Introduction I hope that everyone reading this has a baseline knowledge of Amarin ( AMRN ), its sole product Vascepa, and the REDUCE-IT cardiovascular outcomes trial, or CVOT. Further, presumably everyone is aware of AMRN's recent revelation of positive topline results of REDUCE-IT, with … read more...

Amarin: New Vascepa Prescriptions Grow After REDUCE-IT's Topline Results

via: SeekingAlpha at 2018-11-09 12:29:07:000

The presentation and discussion of Amarin's ( AMRN ) REDUCE-IT detailed results for Vascepa is scheduled for this weekend . If the detailed results match up with the promise of the topline results, it should confirm Amarin as a top acquisition target and drive rapid sales growth for Vascepa… read more...

Amarin: New Vascepa Prescriptions Grow After REDUCE-IT's Topline Results

via: SeekingAlpha at 2018-11-09 12:29:07:000

The presentation and discussion of Amarin's ( AMRN ) REDUCE-IT detailed results for Vascepa is scheduled for this weekend . If the detailed results match up with the promise of the topline results, it should confirm Amarin as a top acquisition target and drive rapid sales growth for Vascepa… read more...

Celgene Does Not Have A Growth Catalyst - Cramer's Lightning Round (11/6/18)

via: SeekingAlpha at 2018-11-07 06:36:54:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, November 6 . Bullish Calls BlackRock (BLK): It yields 3% and CEO Larry Fink is smart. Cramer thinks it's time to buy the stock. Canada Goose (GOOS): Hold on to it. It's a winner. Bearish Call… read more...

Celgene Does Not Have A Growth Catalyst - Cramer's Lightning Round (11/6/18)

via: SeekingAlpha at 2018-11-07 06:36:54:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, November 6 . Bullish Calls BlackRock (BLK): It yields 3% and CEO Larry Fink is smart. Cramer thinks it's time to buy the stock. Canada Goose (GOOS): Hold on to it. It's a winner. Bearish Call… read more...

Big Month For AVEO Pharmaceuticals Inc.

via: SeekingAlpha at 2018-11-06 15:21:07:000

Editor's note: Seeking Alpha is proud to welcome Joseph Heglin as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Tivozanib … read more...

A Migrating Biotech Bear

via: SeekingAlpha at 2018-11-06 08:39:35:000

Biotech Pulse Biotechnology is in a Bear Market. At least the midcap and smallcap segment of it. The S&P Biotechnology Select Index ( XBI ), which is weighted towards the midcap and smallcap companies, has dropped 24% from its high recorded on August 30 to its lowest point past Monda… read more...

Twitter, Sentiment Analysis, And An October Biotech Recap

via: SeekingAlpha at 2018-11-05 15:07:36:000

I first got started in biotech investing by a mentor that had spent years investing and writing about biotech. His colleague, a bit of a guru in the industry, got me started on Twitter, citing it as one of the most important professional tools in his career in equity research. I have since com… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action

via: SeekingAlpha at 2018-11-02 07:59:00:000

Abiomed (NASDAQ: ABMD ) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket. More news on: ABIOMED, Inc., Emergent BioSolutions Inc., Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the mov… read more...

JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action

via: SeekingAlpha at 2018-11-02 07:59:00:000

Abiomed (NASDAQ: ABMD ) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket. More news on: ABIOMED, Inc., Emergent BioSolutions Inc., Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the mov… read more...

JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action

via: SeekingAlpha at 2018-11-02 07:59:00:000

Abiomed (NASDAQ: ABMD ) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket. More news on: ABIOMED, Inc., Emergent BioSolutions Inc., Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the mov… read more...

Amarin Corporation PLC (AMRN) CEO John Thero on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 13:47:14:000

Amarin Corporation PLC (AMRN) Q3 2018 Earnings Conference Call November 01, 2018 07:30 AM ET Executives Elisabeth Schwartz - Senior Director of Investor Relations John Thero - President and Chief Executive Officer Michael Kalb - Senior Vice President and Chief Financial Officer … read more...

Amarin Corporation PLC 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-11-01 11:39:02:000

The following slide deck was published by Amarin Corporation PLC in conjunction with their 2018 Q3 earnings Read more … read more...

Trevena Pushes All-In With Oliceridine

via: SeekingAlpha at 2018-11-01 09:51:54:000

Editor's note: Seeking Alpha is proud to welcome NJ Biotech Expert as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Trevena… read more...

The Biotech Bumps

via: SeekingAlpha at 2018-11-01 08:00:45:000

We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October… read more...

Amarin Q3 revenues up 17%; shares down 3% premarket

via: SeekingAlpha at 2018-11-01 07:51:08:000

Amarin ( AMRN ) Q3 results: Revenues: $55.3M (+16.7%); Product revenue: $55M (+16.8%); Licensing revenue: $0.4M (+33.3%). More news on: Amarin Corporation PLC, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Amarin beats by $0.04, misses on revenue

via: SeekingAlpha at 2018-11-01 05:09:01:000

Amarin (NASDAQ: AMRN ): Q3 Non-GAAP EPS of -$0.06 beats by $0.04 ; GAAP EPS of -$0.08 beats by $0.02 . More news on: Amarin Corporation PLC, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-10-31 17:30:40:000

AAON , AAWW , ABMD , AGIO , ALE , AMAG , AMCX , AME , AMRN , ARES , AROC , ARW , AVP , AYR , BCE , BID , BLL , BMCH , BSIG , CBRE , CCOI , CEIX , CHD , CHSP , CI , CJ , CNQ , CNSL , CWT , D , DM , DNOW , DWDP , EEX , EGRX , EPAM , EXC , EXLS , FLWS , F… read more...

Amarin Corp.: A Valuation

via: SeekingAlpha at 2018-10-31 15:07:44:000

Amarin Corporation PLC's ( AMRN ) stock gained almost 1,000 percent this year so far. The uptake is mainly attributed to the price increase the stock saw since the middle of September. AMRN shot up from around $3 to over $15 as the market responded positively to Vascepas strong results… read more...

This Stock Reset Requires Patience

via: SeekingAlpha at 2018-10-29 15:53:28:000

Halloween is here, but the goblins seem to have lost their way into the stock market. And they're creating havoc! The relentless volatility and a drip of near-daily 1-2% decline are darkening investor confidence and making it a month of terror. What started as a question of whether the Feder… read more...

This Stock Reset Requires Patience

via: SeekingAlpha at 2018-10-29 15:53:28:000

Halloween is here, but the goblins seem to have lost their way into the stock market. And they're creating havoc! The relentless volatility and a drip of near-daily 1-2% decline are darkening investor confidence and making it a month of terror. What started as a question of whether the Feder… read more...

Stronger than expected earnings lead stocks higher premarket

via: SeekingAlpha at 2018-10-29 09:27:38:000

Red Hat (NYSE: RHT ) +49% on being acquired by IBM. More news on: Red Hat, Inc., Diana Containerships Inc., China Recycling Energy Corporation, Stocks on the move, , Top stock market news, Read more … read more...

Stronger than expected earnings lead stocks higher premarket

via: SeekingAlpha at 2018-10-29 09:27:38:000

Red Hat (NYSE: RHT ) +49% on being acquired by IBM. More news on: Red Hat, Inc., Diana Containerships Inc., China Recycling Energy Corporation, Stocks on the move, , Top stock market news, Read more … read more...

Amarin initiates mandatory exchange of $30M of senior debt

via: SeekingAlpha at 2018-10-19 16:40:59:000

Amarin (NASDAQ: AMRN ), through its wholly owned subsidiary Crosicano II Designated Activity Company, exercises its option to exchange all of the outstanding $30M of its 3.50% January 2017 Exchangeable Senior Notes due 2047 into American Depositary Shares (ADSs) at ~$3.89 per ADS (257.2016… read more...

Amarin initiates mandatory exchange of $30M of senior debt

via: SeekingAlpha at 2018-10-19 16:40:59:000

Amarin (NASDAQ: AMRN ), through its wholly owned subsidiary Crosicano II Designated Activity Company, exercises its option to exchange all of the outstanding $30M of its 3.50% January 2017 Exchangeable Senior Notes due 2047 into American Depositary Shares (ADSs) at ~$3.89 per ADS (257.2016… read more...

Amarin initiates mandatory exchange of $30M of senior debt

via: SeekingAlpha at 2018-10-19 16:40:59:000

Amarin (NASDAQ: AMRN ), through its wholly owned subsidiary Crosicano II Designated Activity Company, exercises its option to exchange all of the outstanding $30M of its 3.50% January 2017 Exchangeable Senior Notes due 2047 into American Depositary Shares (ADSs) at ~$3.89 per ADS (257.2016… read more...

Amarin initiates mandatory exchange of $30M of senior debt

via: SeekingAlpha at 2018-10-19 16:40:59:000

Amarin (NASDAQ: AMRN ), through its wholly owned subsidiary Crosicano II Designated Activity Company, exercises its option to exchange all of the outstanding $30M of its 3.50% January 2017 Exchangeable Senior Notes due 2047 into American Depositary Shares (ADSs) at ~$3.89 per ADS (257.2016… read more...

Amarin initiates mandatory exchange of $30M of senior debt

via: SeekingAlpha at 2018-10-19 16:40:59:000

Amarin (NASDAQ: AMRN ), through its wholly owned subsidiary Crosicano II Designated Activity Company, exercises its option to exchange all of the outstanding $30M of its 3.50% January 2017 Exchangeable Senior Notes due 2047 into American Depositary Shares (ADSs) at ~$3.89 per ADS (257.2016… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

3M's Earnings Could Be Disappointing - Cramer's Lightning Round (10/18/18)

via: SeekingAlpha at 2018-10-19 07:01:04:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, October 18 . Bullish Calls Arrowhead Pharmaceuticals (ARWR): It's a great spec and Cramer likes them for the tie up with Johnson & Johnson (JNJ). AT&T (T): Cramer endorsed AT&T but… read more...

3M's Earnings Could Be Disappointing - Cramer's Lightning Round (10/18/18)

via: SeekingAlpha at 2018-10-19 07:01:04:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, October 18 . Bullish Calls Arrowhead Pharmaceuticals (ARWR): It's a great spec and Cramer likes them for the tie up with Johnson & Johnson (JNJ). AT&T (T): Cramer endorsed AT&T but… read more...

3M's Earnings Could Be Disappointing - Cramer's Lightning Round (10/18/18)

via: SeekingAlpha at 2018-10-19 07:01:04:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, October 18 . Bullish Calls Arrowhead Pharmaceuticals (ARWR): It's a great spec and Cramer likes them for the tie up with Johnson & Johnson (JNJ). AT&T (T): Cramer endorsed AT&T but… read more...

3M's Earnings Could Be Disappointing - Cramer's Lightning Round (10/18/18)

via: SeekingAlpha at 2018-10-19 07:01:04:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, October 18 . Bullish Calls Arrowhead Pharmaceuticals (ARWR): It's a great spec and Cramer likes them for the tie up with Johnson & Johnson (JNJ). AT&T (T): Cramer endorsed AT&T but… read more...

3M's Earnings Could Be Disappointing - Cramer's Lightning Round (10/18/18)

via: SeekingAlpha at 2018-10-19 07:01:04:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, October 18 . Bullish Calls Arrowhead Pharmaceuticals (ARWR): It's a great spec and Cramer likes them for the tie up with Johnson & Johnson (JNJ). AT&T (T): Cramer endorsed AT&T but… read more...

Cramer's lightning round: Don't be like the Fed if you're holding this stock

via: CNBC at 2018-10-18 18:49:00:000

No summary available. read more...

Premarket Gainers as of 9:05 am (10/12/2018)

via: SeekingAlpha at 2018-10-12 09:27:54:000

CORI +51% on being acquired by Gurnet Point Capital. More news on: Corium International, Inc., India Globalization Capital, Inc, Tetraphase Pharmaceuticals, Stocks on the move, , Top stock market news, Read more … read more...

Premarket Gainers as of 9:05 am (10/12/2018)

via: SeekingAlpha at 2018-10-12 09:27:54:000

CORI +51% on being acquired by Gurnet Point Capital. More news on: Corium International, Inc., India Globalization Capital, Inc, Tetraphase Pharmaceuticals, Stocks on the move, , Top stock market news, Read more … read more...

Premarket Gainers as of 9:05 am (10/12/2018)

via: SeekingAlpha at 2018-10-12 09:27:54:000

CORI +51% on being acquired by Gurnet Point Capital. More news on: Corium International, Inc., India Globalization Capital, Inc, Tetraphase Pharmaceuticals, Stocks on the move, , Top stock market news, Read more … read more...

Premarket Gainers as of 9:05 am (10/12/2018)

via: SeekingAlpha at 2018-10-12 09:27:54:000

CORI +51% on being acquired by Gurnet Point Capital. More news on: Corium International, Inc., India Globalization Capital, Inc, Tetraphase Pharmaceuticals, Stocks on the move, , Top stock market news, Read more … read more...

Premarket Gainers as of 9:05 am (10/12/2018)

via: SeekingAlpha at 2018-10-12 09:27:54:000

CORI +51% on being acquired by Gurnet Point Capital. More news on: Corium International, Inc., India Globalization Capital, Inc, Tetraphase Pharmaceuticals, Stocks on the move, , Top stock market news, Read more … read more...

Amarin: What The Street Hasn't Factored In And Why Amarin Is Worth $80

via: SeekingAlpha at 2018-10-09 14:28:01:000

Full Disclosure First Motorhead, as the pseudonym suggests, is mainly an investor specialized in automotive stocks, and has written several articles on Seeking Alpha about Tesla. We are not pharmaceutical experts, but have invested in certain healthcare stocks over the past 14 years. With th… read more...

Amarin: What The Street Hasn't Factored In And Why Amarin Is Worth $80

via: SeekingAlpha at 2018-10-09 14:28:01:000

Full Disclosure First Motorhead, as the pseudonym suggests, is mainly an investor specialized in automotive stocks, and has written several articles on Seeking Alpha about Tesla. We are not pharmaceutical experts, but have invested in certain healthcare stocks over the past 14 years. With th… read more...

Amarin: What The Street Hasn't Factored In And Why Amarin Is Worth $80

via: SeekingAlpha at 2018-10-09 14:28:01:000

Full Disclosure First Motorhead, as the pseudonym suggests, is mainly an investor specialized in automotive stocks, and has written several articles on Seeking Alpha about Tesla. We are not pharmaceutical experts, but have invested in certain healthcare stocks over the past 14 years. With th… read more...

Lilly Surges On Pipeline News: Analysis And Trading Thoughts

via: SeekingAlpha at 2018-10-08 14:49:36:000

Introduction Eli Lilly ( LLY ) has been on a roll, powered by some fast-growing young products, some resiliency of its older stalwarts, and a promising pipeline. See p. 12 of LLY's Q2 detailed earnings release for a list of sales and yoy growth rates for these drugs. The reason I have rent… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

Amarin Is A Likely Acquisition Target

via: SeekingAlpha at 2018-10-05 13:16:38:000

Amarin's ( AMRN ) share price has continued to surge after its report of strong topline results from its REDUCE-IT study. I sold part of my position in it at around $16.50, but will likely hold the remainder until after the presentation of detailed results on November 10. If the detaile… read more...

Amarin Is A Likely Acquisition Target

via: SeekingAlpha at 2018-10-05 13:16:38:000

Amarin's ( AMRN ) share price has continued to surge after its report of strong topline results from its REDUCE-IT study. I sold part of my position in it at around $16.50, but will likely hold the remainder until after the presentation of detailed results on November 10. If the detaile… read more...

Amarin Is A Likely Acquisition Target

via: SeekingAlpha at 2018-10-05 13:16:38:000

Amarin's ( AMRN ) share price has continued to surge after its report of strong topline results from its REDUCE-IT study. I sold part of my position in it at around $16.50, but will likely hold the remainder until after the presentation of detailed results on November 10. If the detaile… read more...

The Selloff Has Begun - Cramer's Mad Money (10/4/18)

via: SeekingAlpha at 2018-10-05 07:39:33:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , October 4. The selloff has begun and now investors will have to wait to find a bottom only due to the sheer magnitude of the selloff. "When it comes to this decline, I think it's too early to be… read more...

The Selloff Has Begun - Cramer's Mad Money (10/4/18)

via: SeekingAlpha at 2018-10-05 07:39:33:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , October 4. The selloff has begun and now investors will have to wait to find a bottom only due to the sheer magnitude of the selloff. "When it comes to this decline, I think it's too early to be… read more...

The Selloff Has Begun - Cramer's Mad Money (10/4/18)

via: SeekingAlpha at 2018-10-05 07:39:33:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , October 4. The selloff has begun and now investors will have to wait to find a bottom only due to the sheer magnitude of the selloff. "When it comes to this decline, I think it's too early to be… read more...

Your Daily Pharma Scoop: Amarin's Presentation, Trevena's Rally

via: SeekingAlpha at 2018-10-04 12:59:25:000

Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space and also provide quick commentary on other imp… read more...

Amarin: More Room To Run After REDUCE-IT Success

via: SeekingAlpha at 2018-10-04 12:52:47:000

Shares of Amarin ( AMRN ) surged after the company reported overwhelmingly positive topline results from the REDUCE-IT study. The magnitude of effect was impressive a 25% relative risk reduction in the Vascepa group compared to placebo and has significantly exceeded the targeted… read more...

Amarin Corporation PLC (AMRN) Cantor Global Healthcare Brokers Conference (Transcript)

via: SeekingAlpha at 2018-10-03 15:51:06:000

Amarin Corporation PLC (AMRN) Cantor Global Healthcare Conference October 3, 2018, 11:30 AM ET Executives John Thero - CEO Louise Chen - Cantor Analysts Presentation Louise Chen Hi, good morning. I'd like to introduce you to the CEO of Amarin, John Thero. He's going t… read more...

Amarin up 14% amid conference presentation

via: SeekingAlpha at 2018-10-03 14:22:22:000

The company late this morning presented at the Cantor healthcare conference. More news on: Amgen Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healthcare stocks news, Stocks on the move, Read more … read more...

Financial Exchange Stock Talk: Joe McCann On Amarin

via: SeekingAlpha at 2018-10-02 13:50:41:000

Read more … read more...

Your Daily Pharma Scoop: Intra-Cellular Therapies Completes Rolling NDA, Amarin Rallies Further, Insmed's Approval

via: SeekingAlpha at 2018-10-01 11:09:58:000

Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space and also provide quick commentary on other imp… read more...

Premarket Gainers as of 9:05 am (10/01/2018)

via: SeekingAlpha at 2018-10-01 09:26:27:000

SYN +52% . More news on: Synthetic Biologics, Inc., New Age Beverages Corporation, India Globalization Capital, Inc, Stocks on the move, , Top stock market news, Read more … read more...

Amarin up another 15%

via: SeekingAlpha at 2018-09-28 14:26:51:000

Amarin ( AMRN +15.3% ) continues to build on its Monday moonshot following positive results for its fish oil capsule. More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move, Read more … read more...

Amarin up another 15%

via: SeekingAlpha at 2018-09-28 14:26:51:000

Amarin ( AMRN +15.3% ) continues to build on its Monday moonshot following positive results for its fish oil capsule. More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move, Read more … read more...

Amarin up another 15%

via: SeekingAlpha at 2018-09-28 14:26:51:000

Amarin ( AMRN +15.3% ) continues to build on its Monday moonshot following positive results for its fish oil capsule. More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move, Read more … read more...

Amarin Plays Out, CBL Assets Get A Closer Look - The Idea Guide

via: SeekingAlpha at 2018-09-28 13:06:07:000

by Daniel Shvartsman Checking Seeking Alpha and Twitter ( TWTR ) last night after a dinner (Spanish time) was a fairly immersive experience. Between the ongoing rehashing of yesterday's confirmation hearings in Congress for Brett Kavanaugh and, closer to home, the news of the SEC filing su… read more...

Amarin Plays Out, CBL Assets Get A Closer Look - The Idea Guide

via: SeekingAlpha at 2018-09-28 13:06:07:000

by Daniel Shvartsman Checking Seeking Alpha and Twitter ( TWTR ) last night after a dinner (Spanish time) was a fairly immersive experience. Between the ongoing rehashing of yesterday's confirmation hearings in Congress for Brett Kavanaugh and, closer to home, the news of the SEC filing su… read more...

Amarin Plays Out, CBL Assets Get A Closer Look - The Idea Guide

via: SeekingAlpha at 2018-09-28 13:06:07:000

by Daniel Shvartsman Checking Seeking Alpha and Twitter ( TWTR ) last night after a dinner (Spanish time) was a fairly immersive experience. Between the ongoing rehashing of yesterday's confirmation hearings in Congress for Brett Kavanaugh and, closer to home, the news of the SEC filing su… read more...

Amarin Hits A Home Run With REDUCE-IT

via: SeekingAlpha at 2018-09-26 07:46:43:000

Amarin ( AMRN ) appears to have hit a home run with REDUCE-IT's top line results . It announced that REDUCE-IT met its primary endpoint and demonstrated around 25% relative risk reduction [RRR] in major adverse cardiovascular events with the group taking four grams of Vascepa per day compared… read more...

Amarin Hits A Home Run With REDUCE-IT

via: SeekingAlpha at 2018-09-26 07:46:43:000

Amarin ( AMRN ) appears to have hit a home run with REDUCE-IT's top line results . It announced that REDUCE-IT met its primary endpoint and demonstrated around 25% relative risk reduction [RRR] in major adverse cardiovascular events with the group taking four grams of Vascepa per day compared… read more...

Tesla's Stock Is A Battleground - Cramer's Lightning Round (9/25/18)

via: SeekingAlpha at 2018-09-26 05:38:37:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, September 25 . Bullish Calls Goldman Sachs (GS): Cramer likes the stock and advised buying it for the long term. His trust owns the stock too. Service Corporation International (SCI): They are … read more...

Tesla's Stock Is A Battleground - Cramer's Lightning Round (9/25/18)

via: SeekingAlpha at 2018-09-26 05:38:37:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, September 25 . Bullish Calls Goldman Sachs (GS): Cramer likes the stock and advised buying it for the long term. His trust owns the stock too. Service Corporation International (SCI): They are … read more...

Cramer's lightning round: Tesla's stock is too much of a battleground for me

via: CNBC at 2018-09-25 18:51:00:000

No summary available. read more...

In A Best Case, An Amarin Buyout Could Fetch Close To $45, But Important Caveats Still Remain

via: SeekingAlpha at 2018-09-25 17:33:36:000

The biotech story of the week and possibly the year will almost certainly be Amarin ( AMRN ). The companys main drug, Vascepa, is a highly purified EPA prescription Omega-3 that is formulated to take in much higher doses than traditional "fish oil pills". Despite … read more...

Amarin's Vascepa Outcome Marks A Key Turnaround Event

via: SeekingAlpha at 2018-09-25 12:23:44:000

Recently, Amarin ( AMRN ) announced results from its outcomes study known as REDUCE-IT. The outcome of the trial was highly positive, because the primary endpoint was met. This finding is important, because it builds upon prior data from Vascepa. I believe that this recent finding from the… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-09-25 08:31:34:000

Premier (NASDAQ: PINC ) initiated with Overweight rating and $50 (14% upside) price target at Barclays. More news on: Premier, Inc., Agios Pharmaceuticals, Inc., BeiGene, Healthcare stocks news, Stocks on the move, , Read more … read more...

Amarin "Proves It"

via: SeekingAlpha at 2018-09-24 17:44:25:000

Background - comments on PROVE-IT After the real world benefits of a statin were shown in a large scale outcomes trial of high cholesterol patients with Pravachol, and then replicated with Zocor and Mevacor, the next question was what LDL-cholesterol level was a goal for patients at risk of … read more...

Midday Gainers / Losers (09/24/2018)

via: SeekingAlpha at 2018-09-24 12:35:13:000

Gainers: AMRN +233% . SAEX +153% . GBR +41% . JONE +27% . IPCI +26% . XON +23% . CRC +17% . AGTC +16% . PEIX +15% . ACHV +15% . More news on: Amarin Corporation PLC, SAExploration Holdings, Inc., New Concept Energy, Inc., , Stocks on the move, Top stoc… read more...

Citi sees another 5x upside in Amarin

via: SeekingAlpha at 2018-09-24 11:53:44:000

Amarin (NASDAQ: AMRN ) has skyrocketed more than 200% to $10.15 today after its fish oil capsule showed big benefits in a trial of more than 8K patients with elevated risk of heart issues. More news on: Amarin Corporation PLC, Acasti Pharma, Inc., Healthcare stocks news, Stocks… read more...

Premarket Gainers as of 9:05 am (09/24/2018)

via: SeekingAlpha at 2018-09-24 09:20:17:000

AMRN +280% on positive results from REDUCE-IT study. More news on: Amarin Corporation PLC, AzurRX Biopharma, Applied Genetic Technologies Corporation, Stocks on the move, , Top stock market news, Read more … read more...

Amarin reports positive results from REDUCE-IT study; shares up 307% premarket

via: SeekingAlpha at 2018-09-24 07:04:06:000

Amarin (NASDAQ: AMRN ) is up 307% premarket on robust volume in response to its announcement of positive results from its large-scale cardiovascular outcomes study REDUCE-IT trial for Vascepa (icosapent ethyl). Results showed that patients receiving 4 g/day of Vascepa experie… read more...

Amarin shares surge 300% after fish oil capsule showed benefits to heart patients in trial

via: CNBC at 2018-09-24 06:53:00:000

No summary available. read more...

Amarin: The REDUCE-IT Study Data Will Be A Major Catalyst

via: SeekingAlpha at 2018-09-19 07:28:37:000

Amarin Corporation plc ( AMRN ) has a single product called Vascepa in the US market. Vascepa was approved in 2012. It is an ultra-pure, EPA-only omega-3 fatty acid product. Vascepa is like a diet supplement that may reduce triglyceride levels in adult patients with seve… read more...

Amarin: The REDUCE-IT Study Data Will Be A Major Catalyst

via: SeekingAlpha at 2018-09-19 07:28:37:000

Amarin Corporation plc ( AMRN ) has a single product called Vascepa in the US market. Vascepa was approved in 2012. It is an ultra-pure, EPA-only omega-3 fatty acid product. Vascepa is like a diet supplement that may reduce triglyceride levels in adult patients with seve… read more...

Amarin: The REDUCE-IT Study Data Will Be A Major Catalyst

via: SeekingAlpha at 2018-09-19 07:28:37:000

Amarin Corporation plc ( AMRN ) has a single product called Vascepa in the US market. Vascepa was approved in 2012. It is an ultra-pure, EPA-only omega-3 fatty acid product. Vascepa is like a diet supplement that may reduce triglyceride levels in adult patients with seve… read more...

What If Amarin's REDUCE-IT Trial Fails?

via: SeekingAlpha at 2018-09-17 14:49:44:000

With the REDUCE-IT trial readout approaching, it seems appropriate to consider that failure is possible and what happens in such an event. Stakes are very high for Amarin ( AMRN ) with this readout, given that their sole pipeline product is Vascepa. Raising the stakes even higher is the recent… read more...

What If Amarin's REDUCE-IT Trial Fails?

via: SeekingAlpha at 2018-09-17 14:49:44:000

With the REDUCE-IT trial readout approaching, it seems appropriate to consider that failure is possible and what happens in such an event. Stakes are very high for Amarin ( AMRN ) with this readout, given that their sole pipeline product is Vascepa. Raising the stakes even higher is the recent… read more...

The Sangamo Sell-Off And Amarin's Pending Trial - The Idea Guide

via: SeekingAlpha at 2018-09-14 14:30:15:000

by Daniel Shvartsman Today's Idea Guide is a bit of a grab bag with a focus on the long side. There was at least one idea I have had on my radar previously, another I'd like to research more, and a mix of contrarian, obscure, turnaround, and biotech for the remaining long ideas. On the sho… read more...

The Sangamo Sell-Off And Amarin's Pending Trial - The Idea Guide

via: SeekingAlpha at 2018-09-14 14:30:15:000

by Daniel Shvartsman Today's Idea Guide is a bit of a grab bag with a focus on the long side. There was at least one idea I have had on my radar previously, another I'd like to research more, and a mix of contrarian, obscure, turnaround, and biotech for the remaining long ideas. On the sho… read more...

The Sangamo Sell-Off And Amarin's Pending Trial - The Idea Guide

via: SeekingAlpha at 2018-09-14 14:30:15:000

by Daniel Shvartsman Today's Idea Guide is a bit of a grab bag with a focus on the long side. There was at least one idea I have had on my radar previously, another I'd like to research more, and a mix of contrarian, obscure, turnaround, and biotech for the remaining long ideas. On the sho… read more...

Amarin Enters The Home Stretch For Reduce-IT

via: SeekingAlpha at 2018-09-12 16:25:17:000

Amarin's ( AMRN ) REDUCE-IT study is now entering the home stretch, with top-line results expected by the end of September. The results are expected to potentially have a huge impact on Amarin's stock, with failure (defined as a minimal amount of relative risk reduction) pushing its stock do… read more...

Amarin Enters The Home Stretch For Reduce-IT

via: SeekingAlpha at 2018-09-12 16:25:17:000

Amarin's ( AMRN ) REDUCE-IT study is now entering the home stretch, with top-line results expected by the end of September. The results are expected to potentially have a huge impact on Amarin's stock, with failure (defined as a minimal amount of relative risk reduction) pushing its stock do… read more...

Why The REDUCE-IT Trial Will Fail

via: SeekingAlpha at 2018-09-12 09:46:54:000

Editor's note: Seeking Alpha is proud to welcome Caduceus Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more After w… read more...

Why The REDUCE-IT Trial Will Fail

via: SeekingAlpha at 2018-09-12 09:46:54:000

Editor's note: Seeking Alpha is proud to welcome Caduceus Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more After w… read more...

Amarin: Buy This ~$3 Small Cap?

via: SeekingAlpha at 2018-08-28 15:45:14:000

We're fascinated by the words - but where we meet is in the silence behind them . Ram Dass In today's analysis, we take a look at a small cap stock trading under $3.00 per share. The stock looks undervalued in light of some recent events and analyst calls. The option prem… read more...

Amarin: Buy This ~$3 Small Cap?

via: SeekingAlpha at 2018-08-28 15:45:14:000

We're fascinated by the words - but where we meet is in the silence behind them . Ram Dass In today's analysis, we take a look at a small cap stock trading under $3.00 per share. The stock looks undervalued in light of some recent events and analyst calls. The option prem… read more...

Amarin: Buy This ~$3 Small Cap?

via: SeekingAlpha at 2018-08-28 15:45:14:000

We're fascinated by the words - but where we meet is in the silence behind them . Ram Dass In today's analysis, we take a look at a small cap stock trading under $3.00 per share. The stock looks undervalued in light of some recent events and analyst calls. The option prem… read more...

Amarin set to announce results from REDUCE-IT next month; shares up 1% premarket

via: SeekingAlpha at 2018-08-27 08:23:30:000

Amarin (NASDAQ: AMRN ) announces that topline results from its large-scale REDUCE-IT study assessing the cardiovascular effects of Vascepa (icosapent ethyl) should be released before the end of next month. More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move… read more...

Amarin Corporation PLC (AMRN) CEO John Thero on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-01 21:06:05:000

Amarin Corporation PLC (AMRN) Q2 2018 Earnings Conference Call August 01, 2018 07:30 AM ET Executives Elisabeth Schwartz - IR John Thero - President and CEO Mike Kalb - CFO Craig Granowitz - CMO Steven Ketchum - CSO Joe Kennedy - General Counsel Analysts Louise Chen -… read more...

Amarin Corporation PLC (AMRN) CEO John Thero on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-01 21:06:05:000

Amarin Corporation PLC (AMRN) Q2 2018 Earnings Conference Call August 01, 2018 07:30 AM ET Executives Elisabeth Schwartz - IR John Thero - President and CEO Mike Kalb - CFO Craig Granowitz - CMO Steven Ketchum - CSO Joe Kennedy - General Counsel Analysts Louise Chen -… read more...

Amarin Corporation PLC (AMRN) CEO John Thero on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-01 21:06:05:000

Amarin Corporation PLC (AMRN) Q2 2018 Earnings Conference Call August 01, 2018 07:30 AM ET Executives Elisabeth Schwartz - IR John Thero - President and CEO Mike Kalb - CFO Craig Granowitz - CMO Steven Ketchum - CSO Joe Kennedy - General Counsel Analysts Louise Chen -… read more...

Amarin Corporation PLC 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-08-01 14:46:08:000

The following slide deck was published by Amarin Corporation PLC in conjunction with their 2018 Q2 earnings Read more … read more...

Amarin Q2 revenues up 16%

via: SeekingAlpha at 2018-08-01 05:59:43:000

Amarin ( AMRN ) Q2 results : Revenues: $52.6M (+16.4%); Product revenue: $52.5M (+16.9%); Licensing revenue: $0.1M (-66.7%). More news on: Amarin Corporation PLC, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Amarin misses by $0.01, misses on revenue

via: SeekingAlpha at 2018-08-01 05:03:23:000

Amarin (NASDAQ: AMRN ): Q2 EPS of -$0.10 misses by $0.01 . Revenue of $52.64M (+16.4% Y/Y) misses by $3.94M . Press Release More news on: Amarin Corporation PLC, Earnings news and commentary, Healthcare stocks news, read more...

Notable earnings before Wednesday's open

via: SeekingAlpha at 2018-07-31 17:30:43:000

ADP , AMC , AMRN , AN , ARCC , ARII , AVA , BCOR , BDC , BG , BPMC , CG , CHK , CIM , CLH , CPLA , CRTO , CZR , D , DBD , DIN , DM , EGL , EMES , ENR , EPD , ETR , FLOW , FUN , GIB , GLDD , GLPI , GNRC , GPRE , GRMN , HBI , HEP , HPP , HUM , ICL , ID… read more...

Week 29 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-07-15 02:25:07:000

Breakout Forecast Selections for Week 29: Market conditions continue with medium breakout momentum. The positive momentum gauge continues with another full week in yellow (medium) at 34 down from a value of 46 at the end of the prior week. The negative momentum gauge is unchanged from a… read more...

Week 29 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-07-15 02:25:07:000

Breakout Forecast Selections for Week 29: Market conditions continue with medium breakout momentum. The positive momentum gauge continues with another full week in yellow (medium) at 34 down from a value of 46 at the end of the prior week. The negative momentum gauge is unchanged from a… read more...

Week 29 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-07-15 02:25:07:000

Breakout Forecast Selections for Week 29: Market conditions continue with medium breakout momentum. The positive momentum gauge continues with another full week in yellow (medium) at 34 down from a value of 46 at the end of the prior week. The negative momentum gauge is unchanged from a… read more...

Amarin and Mochida inks deal to develop EPA-based drug products and indications

via: SeekingAlpha at 2018-06-12 06:35:38:000

Amarin Corporation (NASDAQ: AMRN ) has entered into a multi-faceted collaboration with Mochida Pharmaceutical Co. More news on: Amarin Corporation PLC, Healthcare stocks news, Read more … read more...

Amarin and Mochida inks deal to develop EPA-based drug products and indications

via: SeekingAlpha at 2018-06-12 06:35:38:000

Amarin Corporation (NASDAQ: AMRN ) has entered into a multi-faceted collaboration with Mochida Pharmaceutical Co. More news on: Amarin Corporation PLC, Healthcare stocks news, Read more … read more...

Amarin and Mochida inks deal to develop EPA-based drug products and indications

via: SeekingAlpha at 2018-06-12 06:35:38:000

Amarin Corporation (NASDAQ: AMRN ) has entered into a multi-faceted collaboration with Mochida Pharmaceutical Co. More news on: Amarin Corporation PLC, Healthcare stocks news, Read more … read more...

Amarin's Valuation Likely To Increase Ahead Of REDUCE-IT

via: SeekingAlpha at 2018-05-30 02:26:15:000

Preface : Clover Biotech Research is dedicated in highlighting biotech companies that demand "valuation reevaluation" prior to major catalysts. The following article will highlight the second in this series. The first highlighted Conatus ( CNAT ) before it, subsequently, appreciated … read more...

Amarin's Valuation Likely To Increase Ahead Of REDUCE-IT

via: SeekingAlpha at 2018-05-30 02:26:15:000

Preface : Clover Biotech Research is dedicated in highlighting biotech companies that demand "valuation reevaluation" prior to major catalysts. The following article will highlight the second in this series. The first highlighted Conatus ( CNAT ) before it, subsequently, appreciated … read more...

Amarin's Valuation Likely To Increase Ahead Of REDUCE-IT

via: SeekingAlpha at 2018-05-30 02:26:15:000

Preface : Clover Biotech Research is dedicated in highlighting biotech companies that demand "valuation reevaluation" prior to major catalysts. The following article will highlight the second in this series. The first highlighted Conatus ( CNAT ) before it, subsequently, appreciated … read more...

Amarin Continues To Chug Along

via: SeekingAlpha at 2018-05-29 03:41:01:000

Amarin ( AMRN ) continues to chug along as it approaches the finish of its REDUCE-IT study. The results for Q1 2018 were lower than initially expected, due to the effect of beginning of the year insurance deductibles on refills. However, Amarin is keeping its guidance for $230 million in net p… read more...

Amarin Continues To Chug Along

via: SeekingAlpha at 2018-05-29 03:41:01:000

Amarin ( AMRN ) continues to chug along as it approaches the finish of its REDUCE-IT study. The results for Q1 2018 were lower than initially expected, due to the effect of beginning of the year insurance deductibles on refills. However, Amarin is keeping its guidance for $230 million in net p… read more...

Amarin Continues To Chug Along

via: SeekingAlpha at 2018-05-29 03:41:01:000

Amarin ( AMRN ) continues to chug along as it approaches the finish of its REDUCE-IT study. The results for Q1 2018 were lower than initially expected, due to the effect of beginning of the year insurance deductibles on refills. However, Amarin is keeping its guidance for $230 million in net p… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

via: SeekingAlpha at 2018-05-27 19:15:05:000

Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...

After Hours Gainers / Losers (05/24/2018)

via: SeekingAlpha at 2018-05-24 17:38:02:000

Gainers: CAVM +6.1% . DECK +4.1% . NWY +3.9% . AMRN +3.8% . MRVL +2.1% . More news on: Cavium Networks, Inc., Deckers Outdoor Corporation, New York & Company, Inc., Stocks on the move, , News on ETFs, Read more … read more...

After Hours Gainers / Losers (05/24/2018)

via: SeekingAlpha at 2018-05-24 17:38:02:000

Gainers: CAVM +6.1% . DECK +4.1% . NWY +3.9% . AMRN +3.8% . MRVL +2.1% . More news on: Cavium Networks, Inc., Deckers Outdoor Corporation, New York & Company, Inc., Stocks on the move, , News on ETFs, Read more … read more...

After Hours Gainers / Losers (05/24/2018)

via: SeekingAlpha at 2018-05-24 17:38:02:000

Gainers: CAVM +6.1% . DECK +4.1% . NWY +3.9% . AMRN +3.8% . MRVL +2.1% . More news on: Cavium Networks, Inc., Deckers Outdoor Corporation, New York & Company, Inc., Stocks on the move, , News on ETFs, Read more … read more...

Institutional Top Ideas Series: Opaleye Management

via: SeekingAlpha at 2018-05-17 01:52:55:000

In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund weve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Amarin's (AMRN) CEO John Thero on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-02 17:16:04:000

Amarin Corporation PLC (AMRN) Q1 2018 Earnings Conference Call May 2, 2018 07:30 am ET Executives John Thero - President and Chief Executive Officer Craig Granowitz - SVP, Chief Medical Officer Mike Kalb - SVP, Chief Financial Officer Elisabeth Schwartz - Senior Director, Inves… read more...

Amarin's (AMRN) CEO John Thero on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-02 17:16:04:000

Amarin Corporation PLC (AMRN) Q1 2018 Earnings Conference Call May 2, 2018 07:30 am ET Executives John Thero - President and Chief Executive Officer Craig Granowitz - SVP, Chief Medical Officer Mike Kalb - SVP, Chief Financial Officer Elisabeth Schwartz - Senior Director, Inves… read more...

Amarin Corporation PLC 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-02 09:30:21:000

The following slide deck was published by Amarin Corporation PLC in conjunction with their 2018 Q1 earnings Read more … read more...

Amarin Corporation PLC 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-02 09:30:21:000

The following slide deck was published by Amarin Corporation PLC in conjunction with their 2018 Q1 earnings Read more … read more...

Amarin Q1 revenues up 27%; shares ahead 3% premarket

via: SeekingAlpha at 2018-05-02 08:19:55:000

Amarin ( AMRN ) Q1 results : Revenues: $43.9M (+26.9%); Product revenue: $43.8M (+27.7%); Licensing revenue: $0.1M (-66.7%). More news on: Amarin Corporation PLC, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Amarin Q1 revenues up 27%; shares ahead 3% premarket

via: SeekingAlpha at 2018-05-02 08:19:55:000

Amarin ( AMRN ) Q1 results : Revenues: $43.9M (+26.9%); Product revenue: $43.8M (+27.7%); Licensing revenue: $0.1M (-66.7%). More news on: Amarin Corporation PLC, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Amarin beats by $0.01, beats on revenue

via: SeekingAlpha at 2018-05-02 05:03:36:000

Amarin (NASDAQ: AMRN ): Q1 EPS of -$0.07 beats by $0.01 . Revenue of $43.92M (+26.8% Y/Y) beats by $0.17M . Press Release More news on: Amarin Corporation PLC, Earnings news and commentary, Healthcare stocks news, read more...

Amarin beats by $0.01, beats on revenue

via: SeekingAlpha at 2018-05-02 05:03:36:000

Amarin (NASDAQ: AMRN ): Q1 EPS of -$0.07 beats by $0.01 . Revenue of $43.92M (+26.8% Y/Y) beats by $0.17M . Press Release More news on: Amarin Corporation PLC, Earnings news and commentary, Healthcare stocks news, read more...

Notable earnings before Wednesday's open

via: SeekingAlpha at 2018-05-01 17:30:44:000

ABC , ACOR , ADP , ALE , AME , AMRN , APTV , ARCC , ASC , AVA , BDC , BG , BPMC , CAMT , CBRE , CDW , CHK , CLH , CLX , CPLA , CRTO , CVS , DBD , DIN , DNOW , EGL , EL , ENBL , ENR , EXC , FLOW , FUN , GIB , GLDD , GNRC , GRMN , HFC , HRS , HSC , HUM … read more...

Notable earnings before Wednesday's open

via: SeekingAlpha at 2018-05-01 17:30:44:000

ABC , ACOR , ADP , ALE , AME , AMRN , APTV , ARCC , ASC , AVA , BDC , BG , BPMC , CAMT , CBRE , CDW , CHK , CLH , CLX , CPLA , CRTO , CVS , DBD , DIN , DNOW , EGL , EL , ENBL , ENR , EXC , FLOW , FUN , GIB , GLDD , GNRC , GRMN , HFC , HRS , HSC , HUM … read more...

After Hours Gainers / Losers (04/12/2018)

via: SeekingAlpha at 2018-04-12 17:36:09:000

Top gainers: NWL +4.8% . AVGO +4.4% . AMRN +3.2% . SAGE +2.5% . GERN +1.5% . More news on: Newell Brands Inc., Broadcom Limited, Amarin Corporation PLC, Stocks on the move, , News on ETFs, Read more … read more...

After Hours Gainers / Losers (04/12/2018)

via: SeekingAlpha at 2018-04-12 17:36:09:000

Top gainers: NWL +4.8% . AVGO +4.4% . AMRN +3.2% . SAGE +2.5% . GERN +1.5% . More news on: Newell Brands Inc., Broadcom Limited, Amarin Corporation PLC, Stocks on the move, , News on ETFs, Read more … read more...

Amarin presents posters in statin-treated patients with reduced kidney function and diabetes or elevated hsCRP with persistent high TG

via: SeekingAlpha at 2018-04-12 07:39:56:000

Amarin Corporation(NASDAQ: AMRN ) presents two posters this week at the National Kidney Foundation 2018 Spring Clinical Meetings in Austin, TX, April 10-14. More news on: Amarin Corporation PLC, Healthcare stocks news, Read more … read more...

Amarin presents posters in statin-treated patients with reduced kidney function and diabetes or elevated hsCRP with persistent high TG

via: SeekingAlpha at 2018-04-12 07:39:56:000

Amarin Corporation(NASDAQ: AMRN ) presents two posters this week at the National Kidney Foundation 2018 Spring Clinical Meetings in Austin, TX, April 10-14. More news on: Amarin Corporation PLC, Healthcare stocks news, Read more … read more...

Amarin: Waiting For REDUCE-IT Results

via: SeekingAlpha at 2018-04-11 03:08:17:000

Amarin ( AMRN ) provided an update on its Q1 2018 net product revenues recently and indicated that those revenues fell short of its previous guidance range. While Amarin did reiterate its full year guidance, it seems less likely that it will beat that guidance as I had previously thought . … read more...

Amarin: Waiting For REDUCE-IT Results

via: SeekingAlpha at 2018-04-11 03:08:17:000

Amarin ( AMRN ) provided an update on its Q1 2018 net product revenues recently and indicated that those revenues fell short of its previous guidance range. While Amarin did reiterate its full year guidance, it seems less likely that it will beat that guidance as I had previously thought . … read more...

After Hours Gainers / Losers (04/06/2018)

via: SeekingAlpha at 2018-04-06 17:34:57:000

Top gainers: CIFS +2.6% . BPT +2.4% . VEON +1.4% . AMRN +1.4% . More news on: China Internet Nationwide Financial Services Inc., BP Prudhoe Bay Royalty Trust, VEON Ltd. ADS, Stocks on the move, , News on ETFs, Read more … read more...

After Hours Gainers / Losers (04/06/2018)

via: SeekingAlpha at 2018-04-06 17:34:57:000

Top gainers: CIFS +2.6% . BPT +2.4% . VEON +1.4% . AMRN +1.4% . More news on: China Internet Nationwide Financial Services Inc., BP Prudhoe Bay Royalty Trust, VEON Ltd. ADS, Stocks on the move, , News on ETFs, Read more … read more...

Your Daily Pharma Scoop: Tenax Surges, Eli Lilly's CYRAMZA, Cellectics Public Offering

via: SeekingAlpha at 2018-04-05 08:00:00:000

A nalysis focus: Tenax Therapeutics Tenax Therapeutics (TENX) rose nearly 100% in early trading on Wednesday as the company announced results of its pre-investigational New Drug (pre-IND) meeting with the FDA with regard to the phase 2 study in the use of levosimendan for treatm… read more...

Amarin Raises Up To $80 Million With An Equity Offering

via: SeekingAlpha at 2018-01-31 12:31:56:000

Amarin ( AMRN ) announced an equity offering that intended to raise $70 million in gross proceeds ($80.5 million if the underwriters' option is exercised). This should bolster Amarin's cash balance (assuming the underwriters' option is exercised) to around $110 million at the time the REDUCE… read more...

Amarin Raises Up To $80 Million With An Equity Offering

via: SeekingAlpha at 2018-01-31 12:31:56:000

Amarin ( AMRN ) announced an equity offering that intended to raise $70 million in gross proceeds ($80.5 million if the underwriters' option is exercised). This should bolster Amarin's cash balance (assuming the underwriters' option is exercised) to around $110 million at the time the REDUCE… read more...

Amarin Raises Up To $80 Million With An Equity Offering

via: SeekingAlpha at 2018-01-31 12:31:56:000

Amarin ( AMRN ) announced an equity offering that intended to raise $70 million in gross proceeds ($80.5 million if the underwriters' option is exercised). This should bolster Amarin's cash balance (assuming the underwriters' option is exercised) to around $110 million at the time the REDUCE… read more...

Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results

via: SeekingAlpha at 2018-01-31 08:00:00:000

Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com… read more...

Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results

via: SeekingAlpha at 2018-01-31 08:00:00:000

Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com… read more...

Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results

via: SeekingAlpha at 2018-01-31 08:00:00:000

Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com… read more...

Premarket Losers as of 9:05 am (1/30/2018)

via: SeekingAlpha at 2018-01-30 09:24:10:000

VTGN -13% after issuing a letter to stockholders as the Company prepares to initiate its Phase 2 study of AV-101 for Major Depressive Disorder. More news on: VistaGen Therapeutics, Inc., The Scotts Miracle-Gro Company, Maxim Integrated Products, Inc., Stocks on the move, Re… read more...

Premarket Losers as of 9:05 am (1/30/2018)

via: SeekingAlpha at 2018-01-30 09:24:10:000

VTGN -13% after issuing a letter to stockholders as the Company prepares to initiate its Phase 2 study of AV-101 for Major Depressive Disorder. More news on: VistaGen Therapeutics, Inc., The Scotts Miracle-Gro Company, Maxim Integrated Products, Inc., Stocks on the move, Re… read more...

Premarket Losers as of 9:05 am (1/30/2018)

via: SeekingAlpha at 2018-01-30 09:24:10:000

VTGN -13% after issuing a letter to stockholders as the Company prepares to initiate its Phase 2 study of AV-101 for Major Depressive Disorder. More news on: VistaGen Therapeutics, Inc., The Scotts Miracle-Gro Company, Maxim Integrated Products, Inc., Stocks on the move, Re… read more...

Amarin "prices" $70M equity offering; shares down 9% premarket

via: SeekingAlpha at 2018-01-30 09:20:01:000

Amarin (NASDAQ: AMRN ) slumps 9% premarket on robust volume in response to its " pricing " of its $70M offering of American Depositary Shares (ADSs). More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move, Read more … read more...

Amarin "prices" $70M equity offering; shares down 9% premarket

via: SeekingAlpha at 2018-01-30 09:20:01:000

Amarin (NASDAQ: AMRN ) slumps 9% premarket on robust volume in response to its " pricing " of its $70M offering of American Depositary Shares (ADSs). More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move, Read more … read more...

Amarin "prices" $70M equity offering; shares down 9% premarket

via: SeekingAlpha at 2018-01-30 09:20:01:000

Amarin (NASDAQ: AMRN ) slumps 9% premarket on robust volume in response to its " pricing " of its $70M offering of American Depositary Shares (ADSs). More news on: Amarin Corporation PLC, Healthcare stocks news, Stocks on the move, Read more … read more...

After Hours Gainers / Losers (1/29/2018)

via: SeekingAlpha at 2018-01-29 17:35:58:000

Top gainers: PTI +13.4% . AR +5.6% . HA +4.7% . APLP +2.9% . More news on: Proteostasis Therapeutics, Antero Resources Corporation, Hawaiian Holdings, Inc., Stocks on the move, Read more … read more...

After Hours Gainers / Losers (1/29/2018)

via: SeekingAlpha at 2018-01-29 17:35:58:000

Top gainers: PTI +13.4% . AR +5.6% . HA +4.7% . APLP +2.9% . More news on: Proteostasis Therapeutics, Antero Resources Corporation, Hawaiian Holdings, Inc., Stocks on the move, Read more … read more...

After Hours Gainers / Losers (1/29/2018)

via: SeekingAlpha at 2018-01-29 17:35:58:000

Top gainers: PTI +13.4% . AR +5.6% . HA +4.7% . APLP +2.9% . More news on: Proteostasis Therapeutics, Antero Resources Corporation, Hawaiian Holdings, Inc., Stocks on the move, Read more … read more...

After Hours Gainers / Losers (1/26/2018)

via: SeekingAlpha at 2018-01-26 17:35:54:000

Top gainers: AMRN +1.9% . SOGO +1.5% . GDS +1.2% . GFI +1.1% . More news on: Amarin Corporation PLC, Sogou, GDS Holdings, Stocks on the move, Read more … read more...

After Hours Gainers / Losers (1/26/2018)

via: SeekingAlpha at 2018-01-26 17:35:54:000

Top gainers: AMRN +1.9% . SOGO +1.5% . GDS +1.2% . GFI +1.1% . More news on: Amarin Corporation PLC, Sogou, GDS Holdings, Stocks on the move, Read more … read more...

After Hours Gainers / Losers (1/26/2018)

via: SeekingAlpha at 2018-01-26 17:35:54:000

Top gainers: AMRN +1.9% . SOGO +1.5% . GDS +1.2% . GFI +1.1% . More news on: Amarin Corporation PLC, Sogou, GDS Holdings, Stocks on the move, Read more … read more...

After Hours Gainers / Losers (1/26/2018)

via: SeekingAlpha at 2018-01-26 17:35:54:000

Top gainers: AMRN +1.9% . SOGO +1.5% . GDS +1.2% . GFI +1.1% . More news on: Amarin Corporation PLC, Sogou, GDS Holdings, Stocks on the move, Read more … read more...

After Hours Gainers / Losers (1/26/2018)

via: SeekingAlpha at 2018-01-26 17:35:54:000

Top gainers: AMRN +1.9% . SOGO +1.5% . GDS +1.2% . GFI +1.1% . More news on: Amarin Corporation PLC, Sogou, GDS Holdings, Stocks on the move, Read more … read more...

After Hours Gainers / Losers (1/26/2018)

via: SeekingAlpha at 2018-01-26 17:35:54:000

Top gainers: AMRN +1.9% . SOGO +1.5% . GDS +1.2% . GFI +1.1% . More news on: Amarin Corporation PLC, Sogou, GDS Holdings, Stocks on the move, Read more … read more...

Amarin: REDUCE-IT Nears Completion

via: SeekingAlpha at 2018-01-26 03:33:37:000

Amarin ( AMRN ) recently announced that its REDUCE-IT study had reached over 90% of its primary event target and that it expects to report top-line study results before the end of Q3 2018. It has also continued to deliver strong Vascepa sales growth prior to REDUCE-IT's completion, with reve… read more...

Amarin: REDUCE-IT Nears Completion

via: SeekingAlpha at 2018-01-26 03:33:37:000

Amarin ( AMRN ) recently announced that its REDUCE-IT study had reached over 90% of its primary event target and that it expects to report top-line study results before the end of Q3 2018. It has also continued to deliver strong Vascepa sales growth prior to REDUCE-IT's completion, with reve… read more...

Amarin: REDUCE-IT Nears Completion

via: SeekingAlpha at 2018-01-26 03:33:37:000

Amarin ( AMRN ) recently announced that its REDUCE-IT study had reached over 90% of its primary event target and that it expects to report top-line study results before the end of Q3 2018. It has also continued to deliver strong Vascepa sales growth prior to REDUCE-IT's completion, with reve… read more...

Amarin: REDUCE-IT Nears Completion

via: SeekingAlpha at 2018-01-26 03:33:37:000

Amarin ( AMRN ) recently announced that its REDUCE-IT study had reached over 90% of its primary event target and that it expects to report top-line study results before the end of Q3 2018. It has also continued to deliver strong Vascepa sales growth prior to REDUCE-IT's completion, with reve… read more...

Amarin: REDUCE-IT Nears Completion

via: SeekingAlpha at 2018-01-26 03:33:37:000

Amarin ( AMRN ) recently announced that its REDUCE-IT study had reached over 90% of its primary event target and that it expects to report top-line study results before the end of Q3 2018. It has also continued to deliver strong Vascepa sales growth prior to REDUCE-IT's completion, with reve… read more...

Amarin: REDUCE-IT Nears Completion

via: SeekingAlpha at 2018-01-26 03:33:37:000

Amarin ( AMRN ) recently announced that its REDUCE-IT study had reached over 90% of its primary event target and that it expects to report top-line study results before the end of Q3 2018. It has also continued to deliver strong Vascepa sales growth prior to REDUCE-IT's completion, with reve… read more...

Your Daily Pharma Scoop: Portola Still Attractive, Johnson & Johnson Reports Q4 Results, Cerus Reports Positive Results

via: SeekingAlpha at 2018-01-25 08:00:00:000

Analysis of top Seeking Alpha coverage: Portola Today we will focus on Portola Pharmaceuticals ( PTLA ), which had an excellent 2017. PTLA has made a decent start to 2018 as well, gaining more than 4%. Earlier this week, PTLA announced an abstract providing interim results from its ong… read more...

Your Daily Pharma Scoop: Portola Still Attractive, Johnson & Johnson Reports Q4 Results, Cerus Reports Positive Results

via: SeekingAlpha at 2018-01-25 08:00:00:000

Analysis of top Seeking Alpha coverage: Portola Today we will focus on Portola Pharmaceuticals ( PTLA ), which had an excellent 2017. PTLA has made a decent start to 2018 as well, gaining more than 4%. Earlier this week, PTLA announced an abstract providing interim results from its ong… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 23, 2018

via: SeekingAlpha at 2018-01-24 06:26:40:000

Market and sector outlook: Another day, another new high for major U.S. equity indexes which are very overbought. VIX is staying above the $10 level. The 10-year yield pulled back today as government bonds rallied (something to follow this week). Biotech indexes continued their upward m… read more...

Premarket Gainers as of 9:05 am (1/23/2018)

via: SeekingAlpha at 2018-01-23 09:24:18:000

RGSE +39% . More news on: RGS Energy, Inc., ChinaNet Online Holdings, Inc., Aethlon Medical, Inc., Stocks on the move, Read more … read more...

Amarin almost there with REDUCE-IT; shares up 28% premarket

via: SeekingAlpha at 2018-01-23 07:06:57:000

Amarin (NASDAQ: AMRN ) is up 28% premarket on light volume in response to its announcement that the large-scale REDUCE-IT cardiovascular outcomes study supporting Vascepa (icosapent ethyl) has reported more than 90% of the targeted 1,612 primary major adverse cardiovascular eve… read more...

Week In Review: Sinocare Eyes $4 Billion Deal For J&J Diabetes Device Business

via: SeekingAlpha at 2018-01-21 10:33:59:000

Deals and Financings Sinocare (SHZ:300298), a diabetes company based in Changsha, may bid as much as $4 billion to acquire Johnson & Johnson's (JNJ) diabetes medical device subsidiaries (see story ). With falling revenues, some of J&J's diabetes-focused companies are exiting from th… read more...

Your Daily Pharma Scoop: Juno Surges On Takeover Rumors, AEterna Zentaris Achieves Another Milestone, Spark Granted ODD

via: SeekingAlpha at 2018-01-18 08:00:00:000

Analysis of Top Seeking Alpha Coverage: Celgene/Juno Today we will discuss the market speculation about Celgene ( CELG ) looking for a target in the CAR-T space to boost its pipeline. The speculation began after a Wall Street Journal report and pushed Juno Therapeutics ( JUNO ) up more t… read more...

Amarin commences VASCEPA clinical development in China

via: SeekingAlpha at 2018-01-17 07:54:22:000

Amarin's(NASDAQ: AMRN ) partner Eddingpharm commences a clinicaltrial ofVascepa (icosapent ethyl) capsulesin a patients with severe hypertriglyceridemia (TG500 mg/dL) in Mainland China. More news on: Amarin Corporation PLC, Healthca… read more...

Amarin (AMRN) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-11 12:55:55:000

The following slide deck was published by Amarin Corporation PLC in conjunction with this Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX